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Summary 
Despite the over 10-years’ experience providing pediatric antiretroviral therapy(ART) 
and implementing different WHO guidelines, data on updated trends (after 2010) in advanced 
disease at ART start, and on long-term survival of children receiving  ART are scarce. Without 
these data, the impact of recent WHO guidelines on early treatment initiation and long-term 
survival remains unclear. First, we examined trends in advanced disease at ART start, then 
described 10-year survival and investigated risk factors of early mortality in children treated with 
ART and lastly examined the association between rapid ART initiation and outcomes (mortality 
and loss to follow-up) of HIV infected. 
We studied children (0-14 years) with HIV who initiated ART at seven Baylor 
International Pediatric AIDS initiative supported clinics in Botswana, Lesotho, Malawi, 
Swaziland, Tanzania, and Uganda. For the first aim, we conducted a pooled cross sectional study 
of children (N=20,605) who initiated ART between 2003 and 2017. We examined the linear 
trends in the proportion of children with advanced disease (over seven periods of ART initiation 
8 
corresponding to WHO guideline implementation period) using the Cochran-Armitage test for 
trend. For the second aim, we conducted a retrospective cohort study of children (N=18,010) 
who initiated ART between 2003 and 2017. We estimated 10-year survival using the Kaplan-
Meier approach and assessed risk factors of early mortality using Cox proportional hazard 
regression. For the third aim, we conducted a retrospective cohort study of children (N=3,299) 
who initiated ART between 2014 and 2017. We examined the association between rapid ART 
initiation and outcomes of children using sub-distribution hazard regression for competing risks, 
treating death and loss to follow-up as competing risks. 
Between 2003-2017, the proportion of children initiating ART with advanced disease 
declined among ages 5-9 years (58.3% to 39.9%; p<0.01) and 10-14 years (61.9% to 38.1%; 
p<0.01), remained the same for ages <2 years (72.7% to 70.6%; p=0.1), and increased for ages 2-
4 years (59.4% to 62.3%; p<0.01).  10-year survival probability %( 95%CI) was 88.9 (88.3-89.5) 
overall, 83.7 (82.5-84.8) in children aged <2 years, 91.9 (90.7-93.0) in those 2-4 years, 92.6 
(91.5-93.6) in 5-9 years and 88.8 (9 87.2-90.2) in 10-14 years. Half of the deaths occurred within 
6–months of therapy. The risk factors of mortality were: baseline age <2 years (aHR 1.41(95% 
CI: 1.11-1.79) compared to 10-14 years; WHO stage 4 (aHR 2.95(95% CI 2.33-2.72) and stage 3 
(aHR 1.36(95% CI: 1.06-1.73) compared to stage 1 and 2 disease;  severe (aHR=6.71, 95% CI 
5.29-8.52) and moderate (aHR=2.64, 95% CI 1.90-3.66) immune suppression compared to 
no/mild immune suppression; and  severe underweight (aHR 1.84 (95% CI 1.48-2.29) compared 
to normal weight-for-age.  The risk of mortality was similar between children who initiated ART 
on the same-day [adjusted sub distributional hazard risk (aSHR) =1.10, 95% CI 0.79, 1.75] and 
those who initiated within 2-7 days (aSHR=1.05, 95% CI 0.77, 1.43) compared to those who 
initiated within 8-90 days. The risk of LTFU was higher in children who initiated ART on the 
9 
same day (aSHR=1.86, 95% CI 1.39, 2.49) and those who initiated within 2-7 days (aSHR=1.83, 
95% CI 1.38, 2.43) compared to those who initiated within 8-90 days.  
The proportion of children with HIV aged 5-14 years who initiate ART with advanced 
disease has reduced, and long-term survival in those treated with ART is good. However, nearly 
two-thirds of children aged <5 years are still initiating ART with advanced disease, early 
mortality is high, and disease severity characteristics were associated with a higher risk of early 
mortality. A significant proportion of those who initiate ART rapidly is lost to follow-up. While 
programs can use the good survival outcome to motivate caretaker to test and initiate ART early 
in children, more work is required to diagnose, initiate and keep children with HIV in care.   
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BACKGROUND  
INTRODUCTION 
For nearly one and a half decades, combination antiretroviral therapy (ART) has been the 
standard approach for treating pediatric HIV in the Eastern and Southern Africa region (ESA), 
and it has improved short-term outcomes of HIV-infected children 1-4. Since the introduction of 
ART, ESA countries have followed the World Health Organization (WHO) guidelines to provide 
ART to HIV infected children. The WHO guidelines have continually changed to recommend 
treating HIV infected children at a younger age, with less severe HIV disease, and with more-
effective first-line ART 5-9. These changes mean that over time children who start ART should be 
younger, have less advanced disease and have better survival. Reports have shown declining 
trends (up to 2010) in median age and proportion of children with advanced HIV disease 10-15. 
Additionally, cohort studies have shown 1-2 year survival probability after ART of 80-90% 3, 4, 
and losses to follow ranging from 2-39% 16, 17  
Pediatric HIV treatment in resource-limited settings, however, continues to face 
challenges, which can affect early HIV diagnosis in children and long-term outcomes (survival 
and LTFU) of HIV infected children. These include limited access to virological tests for early 
infant diagnosis and the continued need to adjust treatment ART doses as the child’s weight 
increases. Moreover, children depend on caregivers to administer their medicines, and when they 
become adolescents, they may not adhere to ART because of non-disclosure or treatment fatigue. 
Poor adherence to ART could lead to treatment failure, disease progression, and death. Despite 
these challenges of providing pediatric ART and the over 10-years’ experience providing 
pediatric ART and implementing different WHO guidelines, data on updated trends (after 2010) 
in baseline line characteristics, and on long-term survival and LTFU of children initiating ART 
15 
are scarce. Without updated trends in baseline characteristics of children at ART initiation, the 
impact of recent WHO guidelines on early treatment initiation remains unclear. Additionally, not 
knowing long-term survival and LTFU of children on ART precludes our understanding of the 
impact of ART programs on long-term survival in HIV infected children.  
Our study aimed to examine temporal changes in baseline characteristics and to 
investigate predictors and rates of long-term survival and loss to follow-up of HIV infected 
children who start ART.  
LITERATURE REVIEW  
The Burden of pediatric HIV in Eastern and Southern Africa is high. 
ESA carries the highest burden of total HIV infections, new HIV infections and HIV-
related morality in the world. In 2017, an estimated 66% (1.2 million of 1.8 million) of children 
living with HIV worldwide were in ESA18, 19. Additionally, 51% (92,000 of 180,000) of new 
pediatric infections were in ESA. The region has made significant progress identifying and 
initiating HIV infected children on ART with currently 59% of children receiving ART 
compared to a 52% global average 19. However, 47% (52,000 of 110,000) of all global pediatric 
HIV deaths are in ESA and HIV is among the top 10 causes of death among children in this 
region 20. In order to decrease pediatric HIV deaths, the ESA countries have adapted and 
implemented the WHO pediatric HIV treatment guidelines. 
Changes in the WHO guidelines for treating HIV infected children. 
WHO HIV treatment guidelines consist of criteria of when to initiate ART in HIV 
infected children and what ARV regimen to use. Since 2004, WHO has released five sets of 
guidelines for treating HIV in children, each providing more simplified criteria than the one 
16 
before (table 1). These guidelines have progressively recommended treating HIV-infected 
children with less advanced disease, at a younger age, and with more effective first-line ART.  
The first guidelines, released in 2004, provided WHO clinical stage criteria and age-
specific immunological (CD4 cell count/percent) thresholds for starting ART in HIV infected 
child (table 1). The second set of guidelines, released in 2006, recommended higher CD4 
thresholds for starting ART than those in 2004. For example, the 2006 guidelines recommended 
initiating ART in children aged <1 year at a CD4 threshold of  <25% compared <20% in 2003. 
The higher the CD4 count or percent, the less severe the disease is.   
In 2010, after the children with HIV early antiretroviral (CHER) trial showed that early HIV 
diagnosis and early ART reduced infant mortality by 76% and HIV progression by 75% 21, WHO 
released a third set of guidelines. These guidelines recommended immediate ART for all HIV 
infected children aged <2 years irrespective of WHO clinical stage or CD4 count and a higher 
CD4 threshold for older children 6. 
 In 2013, the WHO then released the fourth set of guidelines recommending immediate 
ART for all children aged <5yrs and again higher CD4 counts for older children 8. In 2015, 
WHO dropped the clinical and immunological criteria and recommended immediate ART for all 
children aged <15years irrespective of WHO clinical stage or CD4 cell count 9.  Each set of 
guidelines included treatment regimens as shown in table1. The changes in criteria for initiating 
children on ART should be reflected in the baseline characteristics of children who initiate ART. 
Additionally, in 2017, WHO recommended rapid ART initiation (initiating ART within seven 
days upon diagnosis) in all people living with HIV including children. 
17 
Table 1: Summary of the changes in WHO guidelines on when to initiate ART and the First-line ARV medicine 
Guideline  Age 2003 2006 2010 2013 2015 2017 
 
 
 
 
 
 
Criteria for 
initiating 
ART*  
<12 months 
CD4 <20% 
CD4<1500 or                  
<25%                             
Treat all irrespective of 
CD4 or WHO stage  Treat all 
irrespective 
of CD4 or 
WHO stage  
Treat all 
irrespecti
ve of CD4 
or WHO 
stage  
Rapid 
ART 
initiation 
(within 
one week) 
upon 
diagnosis 
and 
medical 
checks  
12-18months  
CD4<750 or 
<20%  18-24 month  
CD4 <350  
 or  <20%     
24-35 month 
CD4 <350              
or <20%  
 CD4<750 or <25% 
36-59 month  
CD4 <350 or 
<15%                 
5-14 years 
CD4 <200                 
or <15% 
CD4 <200 or 
<15%                  
CD4 count <350  CD4<500  
First Line 
ART regimen 
NRTI 1 AZT or d4T 
AZT or d4T 
or ABC 
AZT or ABC or D4T 
<10yrs: ABC or AZT 
≥10yr: TDF or AZT 
NRTI 2 3TC 
Third ARV  
NVP or EFV                                                 
( EFV only if >3yrs and 
>10kg) 
<2 yrs; exposed to  
NVP: LPV/r 
<2 yrs; not exposed to 
NVP: NVP 
2-3 yrs: NVP 
≥3yrs: NVP or EFV 
<3yrs: LPV/r 
≥3 yrs: EFV 
*For all the criteria, children with WHO clinical stage 3 or 4 HIV disease were eligible irrespective of age or CD4 cell criteria 
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Temporal trends in baseline characteristics of children at ART initiation. 
Characteristics of children like age, WHO clinical stage, CD4 count and Weight for Age 
Z-score at diagnosis, entry into care and at ART initiation are measures indicating the duration of 
HIV disease. Characteristics at diagnosis and entry are a measure of early HIV diagnosis, while 
characteristics at ART initiation are a measure of early ART initiation. Early diagnosis and Early 
ART initiation mean children should be diagnosed and started on treatment at a young age and 
without advanced disease(WHO stage 1 or 2) or severe disease( CD4 count > 200 cells/mm3). 
Early HIV diagnosis and Early ART initiation are critical to stop rapid disease progression in 
children and reduce mortality in HIV infected children. Measuring trends in these characteristics, 
therefore, provides a measure of progress towards early HIV diagnosis and early ART initiation 
in HIV-infected children, a major goal of the WHO guidelines. Studies have examined trends in 
baseline characteristics up to 2010, but the trends after 2010 are scarce.  
Temporal trends in baseline characteristics of children starting ART up to 2010.  
Up to 2010, there were decreasing trends in the median age and proportion of children 
with advanced HIV disease (WHO clinical stage 3 or 4) at ART start. However, a substantial 
proportion of children started ART when they were older or with advanced HIV disease. 
Moreover, the trends in the proportion of children who are underweight at ART start are 
inconclusive. 
Studies that have examined trends in baseline characteristics of HIV infected children 
who started ART up to 2010 show decreasing median age and proportion of children with 
advanced HIV disease 10-15. However, in 2009/2010 the median age at the start of ART was still 
high (range 3 -8 years) and half of the children started ART when they had advanced HIV 
19 
 
disease. Moreover, up to 80% of the children under five years of age had advanced HIV disease 
when they started ART 13.  
In addition, studies that measured trends in the proportion of children who are 
underweight at ART start showed conflicting results. For example, a study using the 
International Epidemiology Databases to Evaluate AIDS (IeDEA) in five countries in Southern 
African showed a significant decrease in the proportion of children with moderate/severe 
underweight from 31% to 28% 13. However, a study in South Africa 11, and another in three 
countries in East Africa 10 showed no change in the trend.   
Young age, advanced HIV disease, and moderate or severe malnutrition are associated 
with higher mortality in HIV infected children 1, 3, 10, 22-26. The trends in these baseline 
characteristics could have changed after 2010 because of the changes in WHO guidelines; 
however, data on the trends after 2010 are limited.  
Data on temporal trends in baseline characteristics of HIV infected children starting ART 
beyond 2010 are limited.  
Although most changes in WHO guidelines for treating HIV in children occurred after 
2010, few studies examine temporal trends in baseline characteristics of HIV infected children 
initiating ART beyond 2010, and they show mixed results.  For example, in the IeDEA cohort 
study of HIV infected children started on ART in three Central African countries (Burundi, 
Democratic Republic of Congo and Rwanda), the proportion of children with advanced HIV 
disease decreased from 55% in 2004/2005 to 42% in 2012/201312. In contrast, in a cohort study 
in Tanzania, the proportion of children with advanced HIV disease increased from 46% in 
2005/2007 to 76% in 2013/201427.  Moreover, while in the IeDEA cohort in Central Africa, the 
proportion of children with severe malnutrition decreased from 41% in 2004/2005 to 17% in 
2002/201312, in another cohort study in Tanzania the proportion increased from 26% in 2008-
20 
 
2012 to 62% in 2013/2014 28. Conversely, all three studies found a decreasing trend in the 
median age at ART initiation from 7yrs to 5.8 years in Central Africa, and 6yrs to 4 years in 
Tanzania 12, 27, 28.  
These differences in the proportion of children with advanced disease and severe 
malnutrition may reflect variations in programmatic strategies in implementing guidelines. For 
example, in Tanzania, the program implemented active case finding in in-patient wards, which 
resulted in a higher yield of children with advanced disease. While in central Africa, there was 
expanded early infant diagnosis and the proportion of children identified with less advanced 
disease increased. Notably, in all of the above studies, the median age (4 -5.8yrs), and proportion 
of children with advanced disease (42-76%) or severe malnutrition (17-62%) in the last year of 
the study was high.  
The inconclusive trends after 2010 highlight the need for more studies to examine 
updated trends in baseline characteristics of children starting ART. Knowing the updated trends 
improves our understanding of the impact of more recent WHO guidelines on early treatment 
initiation. Further, we can examine progress towards early diagnosis and early ART initiation. 
Early HIV diagnosis and early ART initiation reduce disease progression and mortality in HIV-
infected children 21.  
Survival among HIV infected children initiated on ART 
Studies using routine ART program data in resource-limited settings (RLS) show 
variability in survival of HIV infected but most have short follow-up periods (1-2 years). 
However, data on long-term survival in RLS are scarce. Most data on long-term survival are 
from high-income countries, and most are cohorts of older children. Challenges of providing 
pediatric ART in high income and RLS differ. Therefore examining long-term survival and 
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predictors of mortality in RLS improves our understanding of the success of long-term ART in 
those settings and identifies opportunities for improvement. 
Short-term survival of HIV infected children initiating ART 
In RLS, cohorts studies using routine ART program report mortality of 4.3-29% 1, 11, 23, 29, 
mortality rates of 1- 6.9/100 person years 2, 10, 15, 22, 25, 30, 31, and survival probability of 90% in 
children on ART 4.  Most of these studies have follow up time of one-two years. The short 
follow-up time could be because the studies were earlier in the ART program before the children 
accrued longer follow-up time or by design. HIV, however, is a chronic disease and its treatment 
is life-long. In RLS, lifelong ART presents challenges that could affect the success of ART and 
long-term survival. For example, additional challenges in RLS may include that health care 
workers need to continually adjust treatment doses to the child’s weight yet follow-up may be 
difficult/inconsistent, appropriate pediatric formulations may be lacking, there are high losses to 
follow-up, and there may be ARV stock-outs. Moreover, children are vulnerable because they 
depend on caregivers-who may be too sick to administer their medicines and as they grow into 
adolescents, they may not adhere to treatment because of non-disclosure of HIV status or 
treatment fatigue. All these challenges could lead to poor long-term adherence to ART, which 
can result in treatment failure, disease progression and death. Despite these challenges, data on 
long-term survival on ART in RLS are scarce. 
Data on long-term survival of HIV infected children initiating ART in RLS are scarce 
Studies examining long-term survival in HIV infected children receiving ART have 
mainly been from high and middle-income countries. These studies report 5-10 year mortality 
rate of 1.2-1.7 per 100 person-years and survival of >94-99% 32-36. Few studies that report long-
term mortality in RLS show 3-4 yr mortality of 3.6-7.7% among all children 3, 15 and 16% in 
infants 24, and survival of 81%3.  More recent report show 8-years survival of 90% in 
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Mozambique 37 and about 89% in Zambia38 .Most of the studies reporting long-term survival are 
among older children (median age 3.5-7 years). These studies do not examine age-specific long-
term survival and yet long-term survival may differ by age because in studies with short-term 
follow-up, the risk of death is higher in younger children than older children 1, 3, 10, 22-26.  
Given the challenges of long-term ART and the scarcity of data on long-term survival in 
HIV infected children and more so age-specific survival in RLS, there is a need to fill this 
knowledge gap. Examining long-term survival would improve our understanding of the success 
of long-term ART and identify opportunities for improvement. 
Risk factors of mortality in HIV infected children receiving ART 
Risk factors for death in HIV infected children receiving ART are well documented but risk 
factors of early and late death are not been described. Young age (<2yrs), advanced disease 
(WHO stage 3 and 4), severe immune suppression (CD4 <200 cell/mm3 in children ≥5yrs or 
CD4percentage <15% in children <5yrs), severe malnutrition and TB disease have been 
associated with a high risk of death 1, 3, 10, 22-25, 30, 37. However, most of these studies modeled the 
variables as fixed covariates and did not examine the risk factors of early (<6 months) and late 
mortality (≥ 6months) independently,yet, 50-60% of mortality in HIV infected children who 
initiate ART is within the first six months 30, 33, 39, and predictors of early (<6 months) and late 
mortality (≥6 months) may differ 33. For example, a cohort study of HIV infected children 
receiving ART in Europe showed that although baseline age and advanced disease were risk 
factors for early death and not late death, time-updated BMI and severe immune suppression 
were risk factors for late death 33.  Examining predictors of late and early death in RLS is 
important because of the difference in infectious disease burden and quality of care between 
high-income countries and RLS.  
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Rapid ART initiation in children living with HIV 
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) set ambitious 
targets described as “95-95-95” targets to end AIDS by 203040. These targets are that 95% of 
people living with HIV know their HIV status, 95% of those diagnosed with HIV initiate and 
sustain ART and 95% of those on ART achieve and maintain viral suppression. To attain these 
targets, children diagnosed with HIV must be linked to HIV care, promptly initiated on ART and 
retained in care. However, 20% of children with HIV are lost to follow up between diagnosis and 
ART initiation 41. After initiating ART mortality ranges from 4.3-29% 1, 11, 23, 29 and  loss to 
follow-up( LTFU)  ranges from 2-39% 10, 16, 17, 28, 29. These high losses to follow-up and mortality 
if not addressed can preclude attainment of the 95-95-95 goals for children by 2035. 
 As a strategy to reduce loss to follow-up and mortality in people living with HIV, the 
World Health Organization in 2017 recommended initiating ART in all people with HIV within 
7-days (including same-day initiation in people who are ready) upon diagnosis.42. This 
recommendation, also called rapid ART initiation, followed trial reports in adults showing rapid 
ART initiation was associated with an increased likelihood of starting ART, reduced mortality, 
and better viral suppression and retention in care as compared to delayed initiation 42-45.  
Although the WHO recommended rapid ART initiation in children as well, data on the 
effect of rapid ART initiation on outcomes of children were limited and inconclusive. Two trial 
conducted among hospitalized children showed no difference in mortality in children who 
initiated ART rapidly versus those on delayed initiation46, an observational study in Malawi 
showed improved outcomes in children with uncomplicated malnutrition 47. None of these 
studies examine if rapid ART initiation is associated with loss to follow-up, Yet observational 
studies in adults show an increased risk of being lost to follow-up after rapid ART initiation 
compared to delayed ART initiation 48, 49. Given the paucity of data on this topic in children, 
24 
 
further research is required to investigate the effect of rapid ART initiation on the outcomes of 
children.   
PUBLIC HEALTH SIGNIFICANCE 
 This study will show trends in advanced in children starting ART in ESA over 15 years 
(2003-2017). Second, we will describe rates and predictors of long-term survival and report the 
association between rapid ART initiation and outcomes of children treated with ART. These 
outcomes will have a positive impact because they improve our understanding of how changes in 
the WHO guidelines over time have affected early treatment initiation and survival of HIV 
infected children. Further, this information could be used for health care planning and 
intervention development at clinic and government levels.  For example, knowledge of predictors 
of mortality and LTFU will inform the development of interventions to improve survival and 
retention in care. Also, long-term survival rates could be used to model pediatric HIV 
epidemiological estimates and life expectancy in HIV infected children, and to guide patient 
decisions and patient education. Findings of the association between rapid ART initiation and 
outcomes of children may be used to inform future revisions of rapid ART initiation guidelines 
in children. Finally, these data provide a benchmark against which future intervention and 
guidelines will be measured. 
SPECIFIC AIMS  
Introduction of ART has led to a reduction in short-term mortality in children 1-4. 
However, pediatric HIV diagnosis and treatment in RLS continues to be challenging because of 
limited access to virological tests for early infant diagnosis, the need for pediatric friendly ARV 
medicines and need for health care providers to continually adjust ARV doses to the child’s 
weight. Even after starting ART, children continue to be vulnerable because they depend on 
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caregivers to administer their medicines, and when they become adolescents, they may not 
adhere to ART because of non-disclosure or treatment fatigue. Poor adherence to ART could 
lead to treatment failure, disease progression, and death, thus affecting long-term outcomes 
(survival and LTFU) in children. To improve outcomes of HIV infected children, WHO 
guidelines for treating children with HIV have changed over time to recommend treating HIV 
infected children at a younger age, with less severe HIV disease, and with more-effective first-
line ART and more recently to initiate ART within seven days from diagnosis 5-9, 42. These 
changes mean that over time children who start ART should be younger, have less advanced 
disease and have better survival.  
Despite the challenges of providing pediatric ART, the over 10-years’ experience 
providing pediatric ART and implementing different WHO guidelines, data on updated trends 
(after 2010) in baseline line characteristics, and on long-term survival and LTFU of children 
initiating ART are scarce. In addition, evidence of the effect of rapid ART initiation on outcomes 
of children with HIV is limited and inconclusive. Without updated trends in baseline 
characteristics of children at ART initiation, the impact of recent WHO guidelines on early 
treatment initiation remains unclear. Additionally, not knowing long-term survival and LTFU of 
children on ART precludes our understanding of the impact of ART programs on long-term 
survival in HIV infected children. Lastly, the lack of evidence of the impact of rapid ART 
initiation limits the uptake of this recommendation.   
The overall objective, of this proposal, is therefore to examine trends in advanced HIV disease 
and to investigate predictors and incidence of mortality and LTFU children who start ART in 
ESA. The specific aims of this proposal are:  
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Aim 1: Examine trends in advanced HIV disease at ART initiation among children 
initiated on ART between 2003-2017 in ESA.  
Hypothesis 1a: we hypothesize that the proportion of children with advanced disease at 
ART initiation will reduce with an increasing calendar year of ART initiation.  
 
Aim 2: Investigate the incidence and predictors of all-cause mortality in HIV infected 
children starting ART during 2003-2017 in ESA. 
2a. Investigate 10-year survival probability in HIV infected children initiating ART during 
2006-2017 in ESA. 
2b. Identify risk factors of early mortality in HIV infected children starting ART during 
2006-2017 in ESA. 
Aim 3: Investigate the association between rapid ART initiation and outcomes (mortality and 
loss to follow-up) of children with HIV who initiated ART between 2014 and 2017 in ESA 
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METHODS 
STUDY SETTING 
 This study was conducted using data from the Baylor International Paediatric AIDS 
Initiative (BIPAI) network clinics in Botswana, Malawi, Swaziland, Lesotho, Tanzania, and 
Uganda. BIPAI, one of the first organizations to provide pediatric HIV care in Africa, started these 
network clinics in partnership with national governments 50. The first clinics were started in 2003 
in Botswana and Uganda. Other clinics were started in Malawi in 2004, in Lesotho and Swaziland 
2005 and Tanzania in 2010. The HIV infected children in these clinics are treated following 
country-specific guidelines, which are adapted from WHO guidelines. These children have 
scheduled visits at least three monthly, and data at all clinics are recoded using the same electronic 
medical record (EMR) system. Altogether, these clinics have enrolled and initiated a cohort of 
over 30,000 HIV infected children on ART. This cohort of children provides an opportunity to 
examine trends in baseline characteristics and long-term outcomes of HIV infected children.  
DATA COLLECTION 
Individual patient data from routine clinic visits were pooled electronically de-identified 
and sent to the study team for cleaning. A data query was developed and used to extract the 
required variables (table 3). Extracted data was exported to a CSV file. New patient identifiers 
(ID) were assigned to each participant and unique identifiers removed. Only date of birth and 
date of enrolment in the clinic were maintained for computing time to event for data analyses. 
The BIPAI data administrator extracted and de-identified the data, retained the link between 
unique identifiers and new ID’s and shared the data de-identified data with the research team for 
cleaning and analysis.  
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AIM SPECIFIC METHODS 
Methods for specific aim 1:  
Aim 1a: Examine trends in advanced HIV disease at ART initiation among children initiated on 
ART between 2003-2017 in ESA.  
Study design 
We conducted a pooled cross sectional study and trend analysis of baseline characteristics of 
cohorts of children who initiated ART between 2003 and 2017. The cohorts of children were 
grouped into seven calendar periods based on the year of ART initiation. The periods also 
correspond to the WHO guideline periods.  
Study participants  
We included all ART-naïve children with HIV aged <15 years who initiated ART between 
1 January 2003 and 31 December 2017 at the COEs. Additionally, children exposed to 
antiretroviral prophylaxis for preventing mother to child HIV transmission were included.  
Variables and definitions 
The baseline variables at ART initiation included age, sex, weight, entry point to care, WHO 
clinical stage and CD4 count, CD4 percent, weight-for-age z-scores (WAZ). The entry points to 
care were the prevention of mother to child HIV transmission(PMTCT) clinic, inpatient ward/TB 
clinic(IPD/TB), outpatient department(OPD), voluntary counseling and testing(VCT), and 
referrals from other health facilities and outreaches(Others). WHO clinical stage and CD4 were 
considered to be “at ART initiation” if they were taken on or at a date closest to the ART 
initiation date within a window of 6-months before until 1-month after ART initiation. Weight 
were those taken ± 1months of ART initiation. WAZ for children aged < 10 years were 
computed using the WHO child growth standards 51, 52 and for children aged 10-14 years, the 
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Centers for Diseases control and prevention (CDC) growth standards were used53. The CDC 
growth standards were used for children ≥ 10 years because the WAZ scores were not available 
in the WHO child growth standards. Advanced HIV disease was defined as having WHO clinical 
stage III or IV disease and/or severe immune suppression for age (CD4% < 25% for children <1 
year of age, <20% for children aged 1-3yrs, < 15% for children 3-5 years and <15% or CD4 
count <200 cell/mm3 for children aged 5-14 years)42, 54. 
The years of ART initiation were grouped into seven calendar periods: 2003-2005, 2006-
2007, 2008-2009, 2010-2011, 2012-2013, 2014-2015, and 2016-2017 as a proxy for when WHO 
guidelines were implemented. The period 2003-2005 is when the 2003 guidelines were 
implemented; 2006-2007 and 2008-2009 represent the 2006 guidelines period; 2010-2011 and 
2012-2013 represent the 2010 guidelines period; 2014-2015 represents the 2013 guidelines 
period, and 2016-2017 represents the 2015 guidelines period. 
Power calculation                                                                               
We estimated the power to detect a significant (p<0.05) linear trend in categorical variables 
using the Cochrane-Armitage trend test and trend in continuous variables using. The data 
categorized into seven groups corresponding to the period of enrolment in care and of ART 
initiation: 2003-2005, 2006-2007, 2008-2009, 2010-2011, 2012-2013, 2014-2015, 2016-2017. 
The total sample size is 25,000 HIV infected children, and the smallest group had 2000 HIV 
infected children. To estimate power, we used proportions and medians from previous trend 
studies from central Africa 12 and in southern African 13 and varied the sample size in each group 
between 500 and 5000. Power estimates from the proportions and medians from each study were 
plotted in separate graphs. The graphs plotted using the data from central African study were 
labeled (a) and those using the southern African study were labeled (b).   A minimum sample 
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size of 800 in each group had 80% power to detect a significant linear trend in each variable (fig 
2a). Since our data has at least 2000 children in each group, the study will have sufficient power 
to detect linear trends in all the baseline characteristics over time. 
Figure 1: Estimated power for trend test for (a) the proportion with WHO stage 3 or 4 disease, 
(b) proportion with severe immune suppression  
 
 
 
 
Data analysis  
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We summarized characteristics at ART initiations using medians (interquartile ranges [IQR]) and 
proportions for continuous and categorical variables respectively. The characteristics at ART 
initiation were analyzed by calendar period of ART initiation. Trends in categorical and 
continuous characteristics over the ordered calendar periods were assessed using the Cochran-
Armitage test and Cuzick’s test for trend respectively.  We examined overall trends in advanced 
disease as well as by age-specific (<2 years, 2-4 years, 5-9 years and 10-14 yrs.) and country-
specific trends. 
 
Methods for specific aim 2 
Aim 2: To investigate the incidence and predictors of all-cause mortality in HIV infected 
children starting ART during 2003-2017 in ESA. 
Study design, and population  
This was a retrospective cohort study using patient-level data pooled from seven BIPAI 
COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. We included children 
with HIV aged <15 years who initiated ART between January 2006 and June 2017 and had two 
or more follow-up visits after ART initiation. Children who were ARV experienced (except for 
exposure to ARVs for PMTCT) at entry into care were excluded. The cohort start date for 
Tanzania was 2010, corresponding to the period when the clinic became operational.  
Study variables and definitions  
  The independent study variables were age, sex, country, weight, height, WHO clinical 
stage, CD4 count, CD4 percent, weight for age Z-scores (WAZ), BMI for age Z scores (BAZ), 
ART regimens, TB diagnosis, hemoglobin levels(Hb) and immune suppression level. The child’s 
weight or height was considered to be at ART start if they were taken ± 1month from the ART 
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start date, while WHO stage and CD4 count or percent at ART start were taken on or at a date 
closest to the ART initiation date within six months before and one month after ART initiation. 
We computed the WAZ for children aged < 10 years and BAZ for all children using the WHO 
child growth standards 51, 52. WAZ for children aged 10-14 years using the Centers for Diseases 
Control and Prevention (CDC) growth standards 53 because this measure was not available for 
the age group in the WHO growth standards. CD4 counts or CD4 percentage were categorized 
into immune suppression levels (no/mild, moderate or severe) for age according to the WHO 
classification 42, 54. The calendar period of ART initiation was categorized into three, 4-year 
periods: 2006-2009, 2010-2013 and 2014-2017 corresponding to WHO guideline periods; 2014-
2017 covered two guideline periods.  
The main outcome variable was all-cause mortality and was defined as death from any 
cause including HIV related and non-HIV related deaths. The date of death was extracted from 
the EMR. If the date was missing, we used the date the chart was closed. Other events that were 
censored in the analysis were lost to follow-up (LTFU), transfer out and active in care. The 
patient was considered LTFU if there was a gap of 90 days between their next clinic appointment 
and the database closure date (December 31, 2017). The date of LTFU was the chart closure 
date, and if the chart was not closed, the patient was censored 90 days after the last scheduled 
appointment. The patient was considered transferred-out if the transfer was documented and the 
date of transfer was that recorded in the chart.  
Statistical analysis  
Patient characteristics at ART initiation were described using summary statistics 
(medians and proportions) by age groups (<2 years, 2-4 years, 5-9 years and 10-14 years). We 
computed overall mortality rates per 100 person-years (PY) and rates within the first six months 
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of ART, at 6-24 months and after 24 months. Kaplan-Meier estimates for 10-year survival 
probability was calculated overall, by age group, country, and calendar period of ART initiation; 
differences in survival curves were tested using the log-rank test. Time to death was computed 
from the date of ART initiation, and children were right-censored at the earliest of either LTFU, 
transfer out, 10-years of follow-up or database closure date. We examined risk factors of 
mortality in the first 6-months and 6-24 months on ART using univariable and multivariable Cox 
proportional hazard regression models. We limited the analysis to the first 24 months to enable 
us to examine the effect of the most recent WHO- treatment guidelines (2014-2017) on survival. 
We used a stepwise regression method to select the most parsimonious model. The criteria for a 
variable to enter and to stay in the model were p≤0.15 and p≤0.05, respectively. Known 
predictors of death, including WHO clinical stage, immune suppression level, and age were 
purposefully included in the analysis. We tested the proportional hazards assumption using the 
Schoenfield test. To avoid loss of information and biased estimates because of missing data, we 
imputed missing CD4, WHO stage, WAZ, and Hb values using multiple imputation by chained 
equations (MICE), using 20 cycles55, 56.  We conducted sensitivity analyses using complete case 
analysis and competing risks analyses with LTFU as the competing risk.    
 
Methods for Specific Aim 3 
Aim 3: Investigate the association between rapid ART initiation and outcomes (mortality and 
loss to follow-up) of children with HIV who initiated ART between 2014 and 2017 in ESA. 
Study design  
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We conducted a retrospective cohort study using electronic medical records of children 
with HIV who initiated ART at seven BIPAI COEs in Botswana, Eswatini, Lesotho, Malawi, 
Tanzania, and Uganda.    
Study participants  
We included ART_naive HIV-infected children aged <15 years who entered HIV care at 
the study sites between January 2014 and 2017, and initiated ART within 90 days of enrolment. 
The 90 days was the median time to ART initiation observed among patients diagnosed at 
enrolment in a global study of access to ART in children 41. However, we also assumed that if 
children were eligible at enrolment, ART should be initiated at most within 90-days. We 
excluded children who initiated ART less than 6-months from the database closure date 
(December 31, 2017).   
Variables and definitions  
Exposure: The exposure was rapid ART initiation, which we defined as initiating ART within 7-
days of enrollment into care 42. We categorized rapid initiation into same-day initiation and 
initiation within 2-7 days. The comparison group was those who initiated ART within 8-90 days 
(delayed initiation). 
Outcome: The outcomes of the study, were all-cause mortality and LTFU. LTFU, defined as 
having a gap of 90 days between the next clinic appointment and the database closure date 
(December 31, 2017). The date of LTFU was the chart closure date, and if the chart was not 
closed, the patient was censored 90 days after the last scheduled appointment. The other 
outcomes were death, transfer out and active in care. The date of death and of transfer out were 
the dates recorded in the EMR, and if missing, the chat closure date was used. Children were 
considered active in care if none of the other outcomes had occurred and they were assigned the 
date of the last visit as the outcome date. 
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Other covariates: Other covariates considered were age, sex, country World Bank income 
category(middle income vs. low income), weight for age Z-scores (WAZ), TB diagnosis, WHO 
clinical disease stage (WHO stage) and immune suppression level and period of initiation(2014-
2015  versus 2015-2016). The WAZ was computed from the weight taken on the ART start date. 
If weights were missing, weight taken ± 1month from ART start date was used. WAZ for 
children aged < 10 years were computed using the WHO child growth standards 51, 52 and for 
children 10-14 years using the Centers for Diseases Control and Prevention (CDC) growth 
standards 53. The CDC growth standards were used for children age 10-14 years because this 
measure was not available in the WHO growth standards. CD4 counts or CD4 percentage cut 
were categorized into immune suppression level (no/mild, moderate or severe) for age according 
to the WHO classification 42, 54. The year of initiation was categorized as 2014-2015 and 2016-
2017.  
Data analysis  
Baseline characteristics at ART initiations were summarized using frequencies and proportions, 
and medians and interquartile ranges (IQR), stratified by the timing of ART initiation. We 
estimated the 24-month cumulative incidence of death and LTFU by time to ART initiation using 
competing risks survival analysis. Death and LTFU were considered competing risks. Person-
time accrued from the ART initiation date to the earliest of LTFU, death, transfer out, 24 months 
of follow-up or the database closure date (December 31, 2017). We assessed the association 
between rapid ART initiation and 24-months’ mortality and LTFU using sub-distribution hazard 
regression analysis for competing risks adjusting for confounders. Confounders were selected 
using stepwise regression using setting the criteria for a variable to enter and stay in the model at 
p=0.15 and p=0.05, respectively. Known risk factors of loss to follow-up were purposefully 
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included.  Conducted a sensitivity analysis excluding the patients who had only one recorded 
visit. We also conducted stratified analysis to explore if age modified the association between 
rapid ART initiation and the outcomes. We imputed missing CD4, WHO clinical stage, WAZ, 
and hemoglobin values using multiple imputation by chained equations (MICE), using 20 cycles 
55, 56. 
HUMAN SUBJECTS, ANIMAL SUBJECTS, OR SAFETY CONSIDERATIONS  
This study was approved by country-specific institutional review boards, Baylor College of 
Medicine IRB and University of Texas Health Science Center at Houston Committee for the 
protection of human subjects. 
Confidentiality: 
The de-identified data were received from BIPAI and stored in a password-protected computer 
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ABSTRACT 
Introduction 
The aim of this study was to examine age- and site-specific trends in advanced HIV disease at 
ART initiation among HIV-infected children. We also examined trends in age and time-to-ART-
initiation.  
Methods 
We analyzed records of HIV-infected children (0-14 years) who initiated ART between 2003-
2017 at seven Baylor International Pediatric AIDS Initiative clinics in 6-African countries. 
Advanced HIV disease was defined as having WHO stage III or IV disease and/or severe 
immune suppression for age according to WHO criteria. Time-to-ART-initiation was measured 
from date of entry into care. We analyzed trends in categorical and continuous variables over 
seven calendar periods from 2003 to 2017 using Cochran-Armitage and Cuzick’s test for trend 
respectively. 
Results 
20,605 children (31.6% aged <2 years, 20.2% 2-4 years, 26.6% 5-9 years and 21.6% 10-14 
years) were included. Half were girls, 33% were from Uganda, 19.8% from Malawi, 13.9% from 
Lesotho, 13.3% from Tanzania, 10.8% from Eswatini and 9.2% from Botswana. Between 2003-
2017, the proportion of children initiating ART with advanced disease declined among ages 5-9 
years (58.3% to 39.9%; p<0.01) and 10-14 years (61.9% to 38.1%; p<0.01), remained the same 
for ages <2 years (72.7% to 70.6%; p=0.1), and increased for ages 2-4 years (59.4% to 62.3%; 
p<0.01). By site, the proportion decreased in Eswatini (69% to 33%), Lesotho (80% to 34%), 
Malawi (94% to 33%), and Tanzania (71% to 69%) (all p<0.01), remained the same in Botswana 
(70% to 52%, p=0.06) and increased in Uganda (46% to 65%; p<0.01). 
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 The median age(IQR) in years at ART initiation increased in Botswana [5.1 (2.2-8.1) to 9.6 
(1.5-12.6)], Eswatini [4.3 (1.6-8.1) to 8.5 (1.7-11.7]; Lesotho [3.9 (1.4-7.9) to 8.4 (2.8-11.5)] and 
Malawi [5.4 (2.2 to 8.5) to 6.6 (1.9-10.8)] (all p’s<0.01), remained the same in Tanzania [4.2 
(1.5-9.5) to 3.3 (1.4-8.9) ; p=0.1] and declined in Uganda [6.7 (3.8-10.6) to 2.1 (0.8-6.2); 
p<0.01]. Time-to-ART-initiation reduced among all children [median (IQR):63 (28 to 184) to 5 
(0 to 22) days]. 
Conclusion 
Between 2003-2017, disease severity at ART initiation declined among children aged 5-14 years, 
remained the same in children <2 years, and increased in those aged 2-4 years. Over time, 
children initiating ART in southern Africa sites were older and less severely ill; those in Eastern 
Africa sites were younger and more severely ill. In 2016-2017, children initiated ART within the 
first week in care, but a substantial proportion did so with advanced disease.  More efforts are 
required to diagnose and initiate children on ART early. 
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INTRODUCTION 
In 2017, an estimated 1.8 million children aged<15 years were living with HIV globally, 
66% of them in Eastern and Southern Africa (ESA)1. Although ESA bears the highest burden of 
pediatric HIV, the region has made significant progress initiating children with HIV on 
antiretroviral therapy (ART). In 2017, 59% of children with HIV in the region were receiving 
ART compared to 52% globally1. ART improves survival in children 2-5; however, disease 
severity at therapy start is an important prognostic factor. Compared with children with less 
advanced disease, those who start ART with advanced disease have a higher risk of death2, 4, 6-11.  
To maximize the benefits of ART in children with HIV, the World Health Organization 
(WHO) provided five sets of normative guidelines on when to initiate ART in children and 
adolescents between 2003 and 201712-15. With more evidence of the benefits of early therapy in 
children and better treatment regimens, each updated version of the guidelines expanded 
treatment initiation criteria to include children with less advanced disease (table 1). The most 
recent guideline (2015) recommends immediate ART upon diagnosis in all children under 15 
years of age. Altogether, the evolution of these guidelines mean that over time children who start 
ART should have less advanced disease.  
Previous studies examining trends in characteristics of children with HIV  initiating ART 
in sub-Saharan African found that, although age and the proportion with advanced disease were 
declining, a substantial proportion of children still initiated ART with advanced disease6, 16-20. 
Most of these studies examined trends in characteristics up to 2010. Those that examine trends 
beyond 2010, a period when WHO guidelines for ART initiation have changed most, are few17, 
21. Moreover, data on age-specific trends are scarce; yet, until 2015, WHO recommended 
different treatment initiation guidelines by age group (Table 1). Examining trends beyond 2010 
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will improve our understanding of the impact of more recent WHO guidelines on early treatment 
initiation. Furthermore, examining age-specific trends may highlight the differential impact of 
the WHO guidelines on early treatment initiation by age group and identify opportunities to 
improve early treatment initiation. The objective of our study was to examine age- and site-
specific trends in advanced HIV disease among children with HIV who initiated  ART in Eastern 
and Southern Africa between 2003 to 2017. We also examined trends age at ART initiation and 
overall time-to-ART-initiation.  
Table 1: The changes in the WHO recommended criteria for initiating ART in children 
Guideline  Age 2003 2006 2010 2013 2015 
 
 
 
 
 
 
Criteria for 
initiating 
ART*  
<12 months 
CD4 
<20% 
CD4<1500 
or                  
<25%                             
Treat all 
irrespective of 
CD4 or WHO 
stage  
Treat all 
irrespective of 
CD4 or WHO 
stage  
Treat all 
irrespective of 
CD4 or WHO 
stage  
12-
18months  
CD4<750 
or <20%  
18-24 
month  
CD4 <350  
 or  <20%     
24-35 
month CD4 <350              
or <20%  
 CD4<750 or 
<25% 36-59 
month  
CD4 <350 
or <15%                 
5-14 years 
CD4 <200                 
or <15% 
CD4 <200 
or <15%                  
CD4 count 
<350  
CD4<500  
*For all the criteria, children with WHO clinical stage 3 or 4 HIV disease were eligible irrespective of age or CD4 cell 
criteria 
 
 
METHODS 
Study design, setting, and participants 
We conducted a pooled cross sectional study and trend analysis of the proportional of 
children with advanced HIV disease at ART initiation and time to ART initiation in seven 
cohorts of children with HIV who initiated ART between 2003-2017. The cohorts were defined 
by the calendar periods of ART initiation (2003-2005, 2006-2007, 2008-2009, 2010-2011, 2012-
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2013, 2014-2015, and 2016-2017 which are a proxy for when WHO guidelines were 
implemented in the study sites.  
The children were from seven Baylor International Paediatric AIDS Initiative (BIPAI) 
centers of excellence (COE’s) in six countries in Eastern and Southern Africa (Botswana, 
Eswatini, Lesotho, Malawi, Tanzania, and Uganda). BIPAI started each COE in partnership with 
the host governments. The first clinics were started in 2003 in Botswana and Uganda, and later in 
2004 in Malawi, 2006 in Lesotho and Swaziland and 2010 in Tanzania (2 COE’S). These COEs 
provide free HIV prevention, care, and treatment services in line with country-specific guidelines 
that are adapted from WHO guidelines, and they use a standardized electronic medical records 
system.  
We included all ART-naïve children with HIV aged <15 years who initiated ART between 
1 January 2003 and 31 December 2017 at the COEs. Additionally, children exposed to 
antiretroviral prophylaxis for preventing mother to child HIV transmission were included. The 
data were de-identified from routine patient management records, which were extracted and pooled 
electronically.  
Variables and definitions 
The baseline variables at ART initiation included age, sex, weight, entry point to care, 
WHO clinical stage and CD4 count, CD4 percent, and weight-for-age z-scores (WAZ). The entry 
point to care were the prevention of mother to child HIV transmission(PMTCT) clinic, inpatient 
ward/TB clinic(IPD/TB), outpatient department(OPD), voluntary counseling and testing(VCT), 
and referrals from other health facilities and outreaches(Others). WHO clinical stage and CD4 
were considered to be “at ART initiation” if they were taken on or at a date closest to the ART 
initiation date within a window of 6-months before until 1-month after ART initiation. Weight 
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were those taken ± 1months of ART initiation. WAZ for children aged < 10 years were 
computed using the WHO child growth standards22, 23 and for children aged 10-14 years, the 
Centers for Diseases control and prevention (CDC) growth standards were used24. The CDC 
growth standards were used for children ≥ 10 years because the WAZ scores were not available 
in the WHO child growth standards.  
Advanced HIV disease was defined as having WHO clinical stage III or IV disease 
and/or severe immune suppression for age (CD4% < 25% for children <1 year of age, <20% for 
children aged 1-3yrs, < 15% for children 3-5 years and <15% or CD4 count <200 cell/mm3 for 
children aged 5-14 years)25, 26.Time to ART initiation was computed from the date of entry into 
care to the date of ART initiation. The dates of entry into care were grouped into similar calendar 
periods as the years of ART initiation.  
Data analysis  
We summarized characteristics at ART initiations using medians (interquartile ranges 
[IQR]) and proportions for continuous and categorical variables respectively. The characteristics 
at ART initiation were analyzed by calendar period of ART initiation. Trends in proportions of 
children with advanced disease and Trends in time to ART initiation over the ordered calendar 
periods were assessed using Cochran-Armitage test and Cuzick’s test for trend respectively.  We 
examined trends in advanced HIV disease overall, by age-group (<2 years, 2-4 years, 5-9 years 
and 10-14 yrs.) and country. The data from two sites in Tanzania were combined.  
Ethical approval  
This study was approved by country-specific institutional review boards, Baylor College of 
Medicine IRB and University of Texas Health Science Center at Houston Committee for the 
protection of human subjects. 
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RESULT  
Between 2003 and 2017, 20,605 ART-naïve children initiated ART in seven BIPAI 
COEs in the six African countries and were included in the analysis. Table 2 shows the 
characteristics and entry points to care for all children by country. The largest number of children 
were initiated in Uganda (33%), followed by Malawi (19.8%), Lesotho (13.9%), and Tanzania’s 
2 COE’s (13.3%), Eswatini (10.8%) and Botswana (9.2%). The median (IQR) age at ART 
initiation was 4.7 (1.6 to 9.3) years, range across COEs 3.6 to 5.7 years.  The proportion of boys 
and girls was similar overall and across COEs. The number of children initiating ART increased 
from 1,920 in 2003-2005, peaked at 3,861 in 2010-11 and declined after that to 2,018 in 2016-17 
(Supplementary Table 1). The changes in the number of children initiating ART were similar in 
all countries. The median (IQR) time from enrollment to ART initiation decreased from a peak 
of 63 (28 to 184) days in 2008-2009 to 5 (0 to 22) days in 2016-2017, p<0.01 (Supplementary 
Table 1).   
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Table 2: Characteristics at antiretroviral therapy initiation of children with HIV from 6 countries in Eastern and Southern Africa by 
calendar period of ART initiation: 2003-2017 
Period  
Overall            
N=20,605 
Botswana               
N=1893 
Eswatini                 
N=2222 
Lesotho            
N=2870 
Malawi           
N=4076 
Tanzania            
N=2738 
Uganda          
N=6806                  
Age, median                  
(IQR) years 
4.7       
(1.5 to 9.3) 
5.7 
(1.6 to 10) 
4.9 
(1.5 to 9.4) 
5.1 
(1.4 to 9.7) 
3.6 
(1.5 to 8.6) 
3.9 
(1.4 to 9.1) 
5 
(1.8 to 9.3) 
Age group n(%)        
< 2 year 6513(31.6) 552(29.2) 707(31.8) 954(33.2) 1425(34) 1004(36.7) 1871(27.5) 
2-4 years 4170(20.2) 312(16.5) 420(18.9) 471(16.4) 919(23) 495(18.1) 1553(22.8) 
5-9 years 5476(26.6) 548(28.9) 614(27.6) 777(27.1) 969(23.8) 674(24.6) 1895(27.8) 
10-14 years 4446(21.6) 481(25.4) 483(21.7) 668(23.3) 763(18.7) 565(20.6) 1487(21.9) 
Sex        
Female (%) 10343(50.2) 949(50.2) 1069(48.1) 1438(50.1) 1975(48.5) 1409(51.5) 3503(51.5) 
Advanced disease, n 20042 1849 2201 2854 3975 2697 6466 
Yes (%) 12411(61.9) 1265(68.4) 1445(65.7) 1683(59.0) 2747(69.1) 2033(75.4) 3238(50.1) 
WHO stage  III/IV ,n 18884 1729 2154 2851 3949 2695 5506 
Yes (%) 11449(60.6) 1231(71.2) 1314(61) 1440(50.5) 2522(63.9) 1928(71.5) 3017(54.8) 
Severe immune 
suppression ,n 
17703 1554 2130 2655 2996 2441 5927 
Yes (%) 3593(20.3) 179(11.5) 481(22.6) 606(22.8) 830(27.7) 513(21.0) 984(16.6) 
WAZ, n 20279 1849 2190 2854 4037 2737 6615 
median -2.0 -2.0 -1.7 -2.3 -2.2 -2.4 -1.8 
IQR -3.2 to -1.1 -3.0 to -1.1 -2.8 to -0.8 -3.4 to -1.4 -3.4 to -1.2 -3.6 to -1.3 -2.9 to -0.8 
WAZ<-3sd, yes (%) 5871(29.0) 464(25.1) 483(22.1) 946(33.2) 1380(34.2) 988(36.1) 1610(24.3) 
Care entry point§, n 20049 1840 2196 2518 4049 2701 6745 
PMTCT 726(3.6) 169(9.2) 12(0.5) 95(3.8) 256(6.3) 130(4.8) 64(1.0) 
PITC 7544(37.6) 922(50.1) 83(3.8) 217(8.6) 2928(72.3) 572(21.2) 2822(41.8) 
VCT 6904(34.5) 627(34.1) 1982(90.3) 2145(85.2) 404(10.0) 1267(46.9) 479(7.1) 
Other 4875(24.3) 122(6.6) 119(5.4) 61(2.4) 461(11.4) 732(27.1) 3380(50.1) 
§ PMTCT- prevention of mother to child HIV transmission clinic;IPD-inpatient department;OPD-outpatient department;TB-Tuberculosis unit; VCT- 
voluntary counseling and testing; others - referrals from other health facilities and outreach. 
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Trends in age at ART initiation 
Overall, age at ART initiation fluctuated over time and the change was not significant; 
however, it decreased in some countries, remained stable in some, and increased in others. The 
median (IQR) age changed from 5.9 (2.9-9.2) years in 2003-05 to 4.2 (1.3-9.9) years in 2016-
2017 but the change was not significant; p=0.9 (Figure 1a, supplementary table 1). The median 
age initially decreased between 2003 and 2009, then increased until 2014-15 and declined again 
in 2016-17 (Figure 1a). In Uganda, the median age (IQR) declined from 6.7 (3.8-10.6) years in 
2003-2005 to 2.1 (0.8-6.2) years in 2016-17; p<0.01 with fluctuations similar to those observed 
in the overall median age, while in Tanzania the median age was the same [4.2 (1.5-9.5) years in 
2010-2011 to 3.3 (1.4-8.9) years; p=0.1] (Figure 1a, supplementary table 1). In the other 
countries the median age increased: Botswana [5.1 (2.2-8.1) years to 9.6 (1.5-12.6) years; 
p<0.01]; Eswatini [4.3 (1.6-8.1) years to 8.5 (1.7-11.7) years; p<0.01]; Lesotho [3.9 (1.4-7.9) 
years to 8.4 (2.8-11.5) years; p<0.01] and Malawi (5.4 (2.2 to 8.5) years to 6.6 (1.9-10.8) years; 
p<0.01) (Figure 1b, supplementary table 1). 
Overall, the proportions of children aged <2 years and those aged 10-14 years at ART 
initiation increased over time (supplementary table 1); however, similar to the median age, there 
were variations across countries. Only Botswana had an increase in both proportions 
(supplementary table 1). In Malawi, the proportion of infants decreased, but the proportion of 
adolescents increased, while in Uganda the reverse was true (supplementary table 1). Eswatini 
and Lesotho had no significant change in the proportion of infants but an increase in the 
proportion of adolescents while Tanzania had no significant change in both proportions 
(supplementary table 1). 
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Figure 1: The median ages at initiation by calendar period. (a) in all countries, Tanzania and 
Uganda; (b) in Botswana, Lesotho, Malawi, and Eswatini
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Age-specific trends in advanced disease at ART initiation  
Overall, there was a decline in the proportion of children with advanced disease but the 
trend varied by age group. The proportion of children with advanced disease declined from 
65.3% in 2003-05 to 59.5% in 2016-17; p<0.01 (Fig 2a, supplementary table 2). Initially, the 
proportion plateaued between 2003 and 2013, and it declined after that.  
By age group, the proportion remained the same in children <2years (72.7% to 70.6%; 
p=0.1), increased slightly in children aged 2-4 years (59.4% to 62.3%; p<0.01), but decreased in 
children aged 5-9 years (58.3% to 39.9%; p<0.01) and among adolescents aged 10-14 years 
(61.9% to 38.1%; p<0.01) (Fig 2b, supplementary table 2). Although the trend was insignificant 
among infant, the proportions fluctuated over time.  The proportion initially declined from 2003-
2011, then it increased to a peak in 2014-2015, and then declined. The proportion in those 2-4 
years increased to a peak in 2012-13 and then declined. The proportion in those aged 5-9 and 10-
14 plateaued from 2003 to 2013 and declined after that.  
Site-specific trends in advanced disease at ART initiation  
By country, the proportion of children who initiated ART with advanced disease 
decreased in all the countries except Botswana where it remained the same and in Uganda where 
it increased. Among countries where the proportion decreased, the magnitude of the decline 
varied. The proportion decreased by nearly two-thirds in Malawi (94% to 33%; p<0.01), by half 
in Eswatini (69% to 33%; p<0.01) and Lesotho (80% to 34%; p<0.01) (Fig 2c, supplementary 
table 1), and by 12% in Tanzania (79% to 69%; p <0.01) (Fig 2d, supplementary table 1). In 
Botswana, the proportion remained similar (70% to 52%, p<0.06) while in Uganda, the 
proportion increased by 40% (46% to 65%; p<0.01). (Figures 2c-2d, supplementary table 1). At 
the end of the analysis period, more than half of the children in Tanzania, Uganda, and Botswana 
initiated ART with advanced disease.
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Figure 2: The proportion of children with advanced HIV disease at ART initiation by calendar period. (a) All the six countries 
combined (b) By age group (c and d) by country.           
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DISCUSSION 
 
This study of 20,605 children with HIV from seven BIPAI COE’s in six countries in ESA 
documents trends in age and advanced HIV disease at ART start between 2003 and 2017. We 
found that disease severity at ART initiation among children aged 5-14 years has declined, 
remained the same in children <2 years and has increased in those aged 2-4 years. Over time, 
children initiating ART in most Southern Africa sites are older, and less severely ill, while those 
in Eastern Africa sites are younger and more severely ill. In 2016-2017, children initiated ART 
within the first week in care but a substantial proportion especially those aged <5yrs still initiated 
ART with advanced disease.  More efforts are required to diagnose and initiate children on ART 
early. 
Although the change in age over time was not significant, the fluctuations over time may 
reflect changes in WHO guidelines and MTCT rates. The initial decline in median age between 
2006 and 2009 is likely due to increased access to early infant diagnosis and WHO 
recommendation to initiate ART immediately in all children <2 years13. As a result, more young 
children were identified and initiated on ART as is evidenced by the doubling of the proportion 
of children <2 years between 2006 and 2009 (Table 3). This initial decline is similar to that 
reported in previous studies6, 17, 19, 21. After 2009, we observed an increase up to a peak in 2014-
15. During that period, we observe a decline in the proportion of infants and an increase in the 
proportion of adolescents hence increased median age. There are two possible explanations for 
this increase. First, from 2010 onwards, new pediatric infections began to decrease in most 
countries following the implementation of Option A and Option B+ guidelines for PMTCT1. 
Second, the backlog of older children not yet initiated on ART became eligible when the WHO 
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guidelines were revised to treat all children aged <5 years and all <15yrs in 2013 and 2015 
respectively; thus, the median age increased. 
The lack of significance in the overall trend in age is also attributable to variations across 
countries. The median age declined in Uganda, remained the same in Tanzania and increased in 
the southern Africa sites. The age group of children being initiated likely drives the differences 
between the countries. In Uganda, the proportion of children <2 years increased over time while, 
the proportion of adolescents decreased. The reverse was true in Eswatini, Lesotho, and Malawi, 
whereas in Botswana both proportions increased. The spike in median age observed in Uganda in 
2014-2015 coincides with the implementation of the test and start guidelines for all children <15 
years27. Uganda started implementing these guidelines in 2014 while the other countries started 
in 2016. The increase in age at ART initiation in southern Africa is a concern. Although it is 
possible that due to a significant reduction in MTCT rate in these countries, the older children 
being diagnosed now are the long-term progressors who missed PMTCT when they were born. 
However, there might be a possibility of sexual transmission, especially in young adolescents. 
Over 50% of the data on mode of transmission were missing and we cannot ascertain the 
possibility of sexual transmission.    
Overall, the proportion of children with advanced disease at ART initiation declined over 
time. This finding is similar to those previously reported6, 16-18. However, our study found that 
the decline observed by examining the proportion in all children (0-14yrs) together masks age 
disparities in trends. We found that the proportion with advanced disease at ART initiation 
remained the same in children <2 years, increased in children aged 2-4 years and declined in 
children aged 5-14 years (Fig 2b). The plausible explanation for the constant proportion of 
children <2 years with advanced disease is disease progression in these children is rapid, and by 
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the time of diagnosis, most may have progressed to advanced disease. A study on disease 
progression in children with HIV showed that by one year of age, 80% of these children have 
shown signs of HIV and 55% have progressed to advanced disease28. Additionally, a closer 
examination of the trend in children <2 years shows a decline in the proportion of those with 
advance disease between 2006 and 2011 (Fig 2b). This decline is likely related to the increased 
availability of EID and the WHO recommendation to treat all children under 2-years irrespective 
of disease severity13. Similar declines have been reported among infants in southern Africa9, 18. 
The increase in the proportion of children <2 years with advanced disease at ART initiation after 
2011 occurred likely because over time, more children <2 years were being diagnosed in the 
inpatient wards than through PMTCT (table 3). Children identified in inpatient wards are more 
likely to have advanced disease than those identified through PMTCT.  
Among children aged 2-4 years, the proportion of those with advanced disease increased 
slightly. As seen among the children <2 years, this increase is likely because increasingly more 
children 2-4 years are being identified through PITC than PMTCT (table 3). Among the children 
5-14 years, we observed decline, which happened after 2013 and is likely due to the 
implementation of the 2013 and 2015 WHO guidelines. The 2013 WHO guidelines expanded the 
CD4 threshold for initiating ART in these children to <500 cells/mm3 and in 2015 recommended 
immediate ART upon diagnosis in these children14, 15. Thus, more children who did not have 
advanced disease became eligible for ART and were initiated, leading to a decline in the 
proportion of children with advanced disease at treatment initiation.  
 Similar to age-specific trends, we observed differences in country-specific trends of the 
proportion of children with advanced disease. There was a decline in the proportion of children 
initiating ART with advanced disease in Eswatini, Malawi, Lesotho, and Tanzania, while the 
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proportion remained the same in Botswana and increased in Uganda. The differences may be 
attributed to the changes in the age of children initiating ART and entry point to care. As we 
observed earlier, the proportion of younger children who initiated ART with advanced disease 
was higher than that in older children (Fig 2b), and studies show that patients identified through 
provider-initiated testing and counseling (PITC) in inpatient wards and outpatients have higher 
odds of having advanced disease than those identified through voluntary counseling and testing 
VCT)29. The countries where the proportion of children with advanced disease declined were 
those where the median age increased and/or enrolled more children through VCT, while in 
Uganda where the proportion increased, the median age declined and a significant proportion of 
children in later years entered care through PITC (Table 3). The scenarios in Botswana and 
Tanzania are different from those in other countries. For example, in Botswana, although the 
median age increased over time, the proportion of those with advanced disease remained high 
and did not change mainly because most of the children were identified through PITC. In 
Tanzania on the other hand, there was a decline in the proportion of children initiating ART with 
advanced disease although the median age remained the same. Importantly, the decline in 
Tanzania was slight and in 2016/2017, it had the highest number of children initiating treatment 
with advanced disease (69.4%).       
Despite some of the declines observed, the proportion of children initiating ART with 
advanced disease is still a concern. The proportion of children with advanced disease in 2016-
2017 is much higher than observed in central Africa 17 and Europe30. Moreover, we found that in 
2016/2017 children initiated ART within five days of entry into care (Fig 1a), meaning most 
children who initiated ART with advanced disease had advanced disease at entry into care. Our 
findings highlight the need to intensify efforts to diagnose and initiate ART early before children 
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develop advanced disease. The benefits of initiating ART with less advanced disease compared 
to advanced disease include better survival 2, 6, 8, 30-33 and better growth and development 34-36. In 
order to improve early diagnosis of HIV in children, programs should focus not only on testing 
children whose mothers are in the PMTCT program but should increase efforts to find those 
whose mothers missed PMTCT. The infants whose mothers missed PMTCT can be identified by 
providing infant testing in immunization clinics37 and implementing provider-initiated testing in 
pediatric inpatient wards and outpatient clinics38-40. Using the point of care early infant diagnosis 
testing could improve linkage to treatment and reduce pre-treatment loss to follow-up41, 42.  
 Our study has multiple strengths: First, it included data for 15 years, which spans over 5- 
periods of WHO guidelines implementation including the most recent “test and start” guidelines. 
This has enabled us to how characteristics of children have changed because of WHO guideline 
changes. Second, by examining age-specific trends in advanced disease, we are able to show 
how guideline changes differentially affected the age groups. Lastly, our study had a large 
sample (20,605) of children from six countries in ESA, which enabled us to compare trends 
across countries. Nevertheless, our study has several limitations, which should be considered 
when interpreting our results. First, there was substantial missing data (30%) for CD4 count and 
CD4 percent especially during the implementation of the test and start guidelines for all children 
(2015-2017). However, during that period, less than 5% of patients had missing data on the 
WHO clinical stage, and hence most patients could be classified as having advanced disease or 
not using clinical stage. Second, there is potential for selection bias since these COE’s received 
children from referral hospitals, and the patients at referral hospitals are usually very sick 
compared to primary care centers. The proportion of children with advanced disease in our study 
may not be representative of general trends for that country due to this referral pattern. Third, the 
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generalizability of our findings to the countries where these clinics are located may be limited 
because the COEs are well resourced and better staffed compared to primary healthcare facilities 
in those countries. Notwithstanding, in some countries, these COEs serve a significant proportion 
of children with HIV in the country which enhances representativeness, e.g., about 30% of all 
children with HIV in Botswana receive care in the COE and about 22% in Lesotho.  Lastly, 
although changes in WHO guidelines explain some of the changes we observe, our study is 
purely descriptive, and it is difficult to attribute causation to guideline changes. Other 
interrelated factors like increased health worker training and increased programmatic funding 
may have contributed to the changes.   
CONCLUSION  
 Our study shows that between 2003 and 2017, disease severity at ART initiation among 
children aged 5-14 years has declined, remained the same in children <2 years and has increased 
in those aged 2-4 years. Over time, children initiating ART in most Southern Africa sites are 
older, and less severely ill, while those in Eastern Africa sites are younger and more severely ill. 
In 2016-2017, children initiated ART within the first week in care but a substantial proportion 
especially those aged <5yrs still initiated ART with advanced disease.  More efforts are required 
to diagnose and initiate children on ART early. 
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Supplementary table 1: Characteristics at antiretroviral therapy initiation and entry point to care of children with 
HIV overall and by country between 2003-2017 §   
Characteristic 
Period of ART initiation p for 
trend 
¥ 2003-05          2006-07             2008-09             2010-11         2012-13               2014-15           2016-17         
All Countries  
N 1920 3113 3363 3861 3223 3107 2018  
Time to ART, median 
(IQR) days 
45 
(15 to 142) 
55 
(28 to 126) 
63 
(28 to 184) 
48 
(18 to 259) 
21 
(7 to 114) 
16 
(3 to 356) 
5 
(0 to 22) 
<0.01 
Age, Median(IQR) years  
5.9         
(2.8 to 9.2) 
4                
(1.6 to 8.4) 
3.8               
(1.4 to 8.5) 
4.4               
(1.5 to 9.2) 
4.5               
(1.4 to 9.7) 
5.9            
(1.7 to 10.3) 
4.2              
(1.3 to 9.9) 
0.9 
<2yrs 332(17.3) 999(32.1) 1181(35.1) 1276(33) 1077(33.4) 905(29.1) 743(36.8) <0.01 
2-4 yrs 480(25) 732(23.5) 712(21.2) 799(20.7) 602(18.7) 517(16.7) 328(16.3)  
5-9 yrs 712(37.1) 857(27.5) 838(24.9) 983(25.5) 789(24.5) 851(27.4) 446(22.1)  
10-14yrs 396(20.6) 525(16.9) 632(18.8) 803(20.8) 755(23.4) 834(26.8) 501(24.8) <0.01 
Advanced disease, n 1832 3025 3282 3750 3174 3051 1928   
Yes (%) 1132(61.8) 1952(64.5) 2043(62.3) 2440(65.1) 2116(66. 7) 1683(55.2) 1045(54.2) <0.01 
Entry point, n 1866 2821 3308 3780 3198 3074 2002   
PMTCT 66(3.5) 127(4.5) 93(2.8) 130(3.4) 119(3.7) 117(3.8) 74(3.7) 
 
PITC 585(31.4) 810(28.7) 1242(37.6) 1510(39.9) 1317(41.2) 1260(41) 820(40.9) 
 
Self-referral/VCT 487(26.1) 1090(38.6) 1361(41.1) 1155(30.6) 1105(34.6) 1020(33.2) 686(34.3) 
 
Other  728(39) 794(28.2) 612(18.5) 985(26.1) 657(20.5) 677(22) 422(21.1) 
 
Botswana 
N 779 186 271 263 164 124 106  
Time to ART, median 
(IQR) days 
17 
(7 to35) 
14 
(0 to 41) 
16 
(0 to 151) 
14 
(1 to 58) 
16 
(6 to 45) 
14 
(5 to 54) 
9 
(3 to 53) 
0.6 
Age, Median(IQR) years  
5.1              
(2.2 to 8.1) 
4.9              
(0.8 to 9.9) 
7.2              
(1.5 to 10.9) 
7.9             
(1.0 to 11.2) 
6.9             
(0.8 to 12.1) 
5.5            
(0.8 to 11.8) 
9.6           
(1.5 to 12.6) 
<0.01 
<2yrs 171(22) 73(39.3) 78(28.8) 87(33.1) 66(40.2) 46(37.1) 31(29.3) <0.01 
2-4 yrs 211(27.1) 22(11.8) 27(10) 20(7.6) 7(4.3) 14(11.3) 11(10.4)  
5-9 yrs 307(39.4) 46(24.7) 74(27.3) 62(23.6) 29(17.7) 17(13.7) 13(12.3)  
10-14yrs 90(11.6) 45(24.2) 92(34) 94(35.7) 62(37.8) 47(37.9) 51(48.1) <0.01 
Advanced disease, n 756 173 264 262 164 124 106   
Yes (%) 528(69.8) 114(65.9) 174(65.9) 190(72.5) 116(70.7) 88(71) 55(51.9) 0.06 
Entry point , n 754 182 265 256 159 119 105   
PMTCT 46(6.1) 21(11.5) 35(13.2) 35(13.7) 16(10.1) 8(6.7) 8(7.6) 
 
PITC 266(35.3) 62(34.1) 128(48.3) 167(65.2) 123(77.4) 93(78.2) 83(79) 
 
Self-referral/VCT 406(53.9) 87(47.8) 83(31.3) 24(9.4) 11(6.9) 11(9.2) 5(4.8) 
 
Other  36(4.7) 12(6.6) 19(7.2) 30(11.7) 9(5.6) 7(5.9) 9(8.6) 
 
§ n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions 
and medians respectively over ordered calendar periods of ART initiation. 
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Supplementary table 1: continued 
Characteristic 
Period of ART initiation p for 
trend 
¥ 2003-05          2006-07             2008-09             2010-11         2012-13               2014-15           2016-17         
Malawi 
N 221 779 892 903 569 405 307  
Time to ART, median 
(IQR) days 
30 
(13 to 75) 
43 
(25 to 90) 
71 
(36 to 166) 
66 
(21 to 332) 
22 
(4 to 155) 
17 
(2 to 362) 
7 
(0 to 175) 
<0.01 
Age, Median(IQR) years  
5.4           
(2.2 to 8.5) 
2.77           
(1.4 to 7.4 ) 
2.51           
(1.2 to 6.6) 
3.79            
(1.6 to 8.5) 
3.91             
(1.4 to 9.4 ) 
5.91            
(2.0 to 10.7) 
6.62           
(1.9 to 10.8) 
<0.01 
<2yrs 49(22.2) 303(38.9) 375(42) 307(34) 201(35.3) 106(26.2) 84(27.4) 0.15 
2-4 yrs 52(23.5) 188(24.1) 219(24.6) 215(23.8) 110(19.3) 84(20.7) 51(16.6)  
5-9 yrs 75(33.9) 170(21.8) 181(20.3) 226(25) 134(23.6) 101(24.9) 82(26.7)  
10-14yrs 45(20.4) 118(15.2) 117(13.1) 155(17.2) 124(21.8) 114(28.2) 90(29.3) <0.01 
Advanced disease, n 221 775 875 884 543 388 289   
Yes (%) 207(93. 7) 649(83.7) 676(77.3) 616(69.7) 327(60.2) 177(45.6) 95(32.9) <0.01 
Entry point, n 221 768 890 894 568 402 306   
PMTCT 20(9.1) 93(12.1) 48(5.4) 52(5.8) 21(3.7) 11(2.7) 11(3.6) 
 
PITC 80(36.2) 417(54.3) 727(81.7) 686(76.7) 454(79.9) 312(77.6) 252(82.3) 
 
Self-referral/VCT 73(33) 183(23.8) 37(4.1) 43(4.8) 27(4.8) 30(7.5) 11(3.6) 
 
Other 48(21.7) 75(9.8) 78(8.8) 113(12.7) 66(11.6) 49(12.2) 32(10.5) 
 
Uganda 
N 920 960 863 1415 920 1085 643  
Time to ART, median 
(IQR) days 
121 
(56 to282) 
93 
(42 to 280) 
92 
(43 to 417) 
51 
(24 to 489) 
15 
(6 to 266) 
14 
(2 to 1204) 
2 
(0 to 7) 
<0.01 
Age, Median(IQR) years  
6.7            
(3.8 to 10.6) 
4.9            
(2.0  to 9.1) 
4.5              
(1.7 to 8.8) 
4.2              
(1.6 to 8.5) 
4.7               
(1.7 to 9.3) 
7.2              
(2.2 to 10.4) 
2.1               
(0.8 to 6.2) 
<0.01 
<2yrs 112(12.2) 235(24.5) 254(29.4) 446(31.5) 259(28.1) 254(23.4) 311(48.4) <0.01 
2-4 yrs 217(23.6) 248(25.8) 216(25) 353(25) 215(23.4) 182(16.8) 122(19)  
5-9 yrs 330(35.8) 279(29.1) 226(26.2) 354(25) 238(25.9) 341(31.4) 127(19.7)  
10-14yrs 261(28.4) 198(20.6) 167(19.4) 262(18.5) 208(22.6) 308(28.4) 83(12.9) <0.01 
Advanced disease, n 855 898 811 1335 912 1061 594   
Yes (%) 397(46.4) 309(34.4) 339(41.8) 782(58.6) 554(60.8) 466(43.9) 391(65.8) <0.01 
Entry point, n 891 949 856 1406 918 1082 643   
PMTCT 0(0) 6(0.6) 0(0) 18(1.3) 17(1.9) 17(1.6) 6(0.9) 
 
PITC 239(26.8) 272(28.7) 362(42.3) 558(39.7) 503(54.8) 582(53.8) 306(47.6) 
 
Self-referral/VCT 8(0.9) 5(0.5) 7(0.8) 129(9.2) 95(10.3) 115(10.6) 120(18.7) 
 
Other  644(72.3) 666(70.2) 487(56.9) 701(49.8) 303(33) 368(34) 211(32.8) 
 
§ n is the available sample size for each variable. ¥ The p-values are from Cochrane Armitage test for categorical variables and 
Cuzick’s test for continuous variables over ordered calendar periods of ART initiation. 
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Supplementary table 1: continued 
Characteristic 
Period of ART initiation p for 
trend ¥ 2006-07             2008-09             2010-11         2012-13               2014-15           2016-17         
Eswatini 
N 565 612 468 206 205 166  
Time to ART, median 
(IQR) days 
56 
(32 to 113) 
56 
(28 to 143) 
46 
(19 to 229) 
55 
(21 to 269) 
42 
(16 to 572) 
28 
(9 to 1367) 
0.2 
Age, Median 
(IQR) years  
4.29             
(1.6 to 8.1) 
4.67                    
(1.5 to 8.8) 
4.25              
(1.3 to 8.9) 
4.74             
(1.5 to 10.5) 
7.24             
(2.0 to 10.8) 
8.54             
(1.7 to 11.7) 
<0.01 
<2yrs 172(30.4) 201(32.8) 170(36.3) 69(33.5) 51(24.9) 44(26.5) 0.5 
2-4 yrs 136(24.1) 115(18.8) 80(17.1) 39(18.9) 34(16.6) 16(9.6)  
5-9 yrs 177(31.3) 173(28.3) 126(26.9) 39(18.9) 58(28.3) 40(24.1)  
10-14yrs 80(14.2) 123(20.1) 92(19.7) 59(28.6) 62(30.2) 66(39.8) <0.01 
Advanced disease, n 557 610 463 202 204 165   
Yes (%) 385(69.12) 446(73.11) 342(73.87) 121(59.9) 97(47.55) 54(32.73) <0.01 
Entry point, n 550 609 464 204 203 166   
PMTCT 6(1.1) 3(0.5) 3(0.6) 0(0) 0(0) 0(0) 
 
PITC 37(6.7) 5(0.8) 4(0.9) 1(0.5) 9(4.4) 27(16.3) 
 
Self-referral/VCT 480(87.3) 579(95.1) 430(92.7) 193(94.6) 180(88.7) 120(72.3) 
 
Referrals from other health 
facilities/outreach  27(4.9) 22(3.6) 27(5.8) 10(4.9) 14(6.9) 19(11.4) 
 
Lesotho 
N 623 725 519 396 361 246  
Time to ART, median 
(IQR) days 
36 
(22 to 79) 
42 
(21 to 126) 
56 
(23 to 333) 
43 
(20 to 189) 
29 
(14 to 272) 
24 
(2 to 764) 
0.08 
Age, Median(IQR) years  
3.9                  
(1.4 to 7.9) 
3.8             
(1.0 to 8.2) 
6.0                
(1.3 to 10.2) 
6.2                
(1.6 to 10.1) 
6.7             
(1.5 to 10.9) 
8.4              
(2.8  to 11.5) 
<0.01 
<2yrs 216(34.7) 273(37.7) 171(33) 134(33.8) 114(31.6) 46(18.7) 0.004 
2-4 yrs 138(22.2) 135(18.6) 67(12.9) 46(11.6) 50(13.9) 35(14.2)  
5-9 yrs 185(29.7) 184(25.4) 147(28.3) 112(28.3) 82(22.7) 67(27.2)  
10-14yrs 84(13.5) 133(18.3) 134(25.8) 104(26.3) 115(31.9) 98(39.8) <0.01 
Advanced disease, n 622 722 513 391 361 245   
Yes (%) 495(79.6) 408(56.5) 301(58.7) 230(58.8) 166(46.0) 83(33.9) <0.01 
Entry point, n 372 688 477 389 349 243   
PMTCT 1(0.3) 7(1) 2(0.4) 26(6.7) 42(12) 17(7) 
 
PITC 22(5.9) 20(2.9) 33(6.9) 36(9.3) 55(15.8) 51(21) 
 
Self-referral/VCT 335(90.1) 655(95.2) 441(92.5) 326(83.8) 240(68.8) 148(60.9) 
 
Other  14(3.7) 6(0.9) 1(0.2) 1(0.3) 12(3.4) 27(11.1) 
 
§ n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions 
and medians respectively over ordered calendar periods of ART initiation. 
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Supplementary table 1: continued 
§ n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test and Cuzick’s test for trends of proportions 
and medians respectively over ordered calendar periods of ART initiation. 
Characteristic 
Period of ART initiation 
p for  
trend¥ 
2006-07             2008-09             2010-11         2012-13               2014-15           2016-17          
Tanzania 
N   293 968 927 550  
Time to ART, median 
(IQR) days 
  
20 
(10 to 45) 
17 
(6 to 53) 
12 
(2 to 41) 
3 
(0 to 14) 
<0.01 
Age, Median(IQR) years      
4.2                  
(1.5 to 9.5) 
4                 
(1.4 to 8.9) 
4.4                  
(1.5 to 9.1) 
3.3                   
(1.3 to 8.9) 
0.1 
<2yrs   95(32.4) 348(36) 334(36) 227(41.3) 0.2 
2-4 yrs   64(21.9) 185(19.1) 153(16.5) 93(16.9)  
5-9 yrs   68(23.2) 237(24.5) 252(27.2) 117(21.3)  
10-14yrs   66(22.5) 198(20.4) 188(20.3) 113(20.5)  
Advanced disease, n     293 962 913 529   
Yes (%)   209(71.33) 768(79.83) 689(75.47) 367(69.38) <0.01 
Entry point, n     283 960 919 539   
PMTCT   20(7.1) 39(4.1) 39(4.2) 32(6.0) 
 
PITC   62(21.9) 200(20.8) 209(22.8) 101(18.7) 
 
Self-referral/VCT   88(31.1) 453(47.2) 444(48.3) 282(52.3) 
 
Other    113(39.9) 268(27.9) 227(24.7) 124(23.0) 
 
60 
 
Supplementary table 2: Age-specific trends in advanced HIV disease at antiretroviral therapy 
initiation among children with HIV in all countries: 2003-2017 §    
Characteristic 
Calendar period of ART initiation  
p for  
trend¥ 
2003-05 2006-07          
N=3113 
2008-09            
N=3363 
2010-11             
N=3861 
2012-13          
N=3223 
2014-15          
N=3107 
2016-17         
N=2018 N=1920 
         
         
< 2 year, n 318 983 1163 1243 1052 868 698   
Yes (%)  231(72.7) 718(73) 805(69.2) 854(68.7) 764(72.6) 668(77) 493(70.6) 0.1 
2-4 years, n 458 713 692 775 597 511 313   
Yes (%) 272(59.4) 431(60.5) 415(60) 488(63) 409(68.5) 336(65.8) 195(62.3) <0.01 
5-9 years, n 682 819 815 952 780 844 426   
Yes (%) 397(58.2) 506(61.8) 459(56.3) 624(65.6) 505(64.7) 386(45.7) 170(39.9) <0.01 
10-14 years, n 374 510 612 780 745 828 491   
Yes (%) 232(62.0) 297(58.2) 364(59.5) 474(60.8) 438(58.8) 293(35.4) 187(38.1) <0.01 
§ n is the available data for each variable. ¥ The p-values are from Cochrane Armitage test for trends of proportions 
over ordered calendar periods of ART initiation. 
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ABSTRACT  
Introduction 
Despite providing pediatric antiretroviral therapy (ART) for >10 years, data on long-term survival of 
HIV-infected children receiving ART in resource-limited settings are scarce. We describe 10-year 
survival and risk factors for early mortality in HIV-infected children receiving ART. 
Methods 
We conducted a retrospective cohort study of HIV-infected children (0-14 years) who initiated ART 
between 2006-2017 at seven centers of excellence in Botswana, Eswatini, Lesotho, Malawi, 
Tanzania, and Uganda. Time to death was measured from the ART initiation date, and children were 
right-censored at the earliest of either LTFU, transfer out, 10-years of follow-up or database closure 
date (Dec 31, 2019). We estimated the 10-year survival probability using Kaplan-Meier methods and 
assessed risk factors for mortality using Cox proportional hazard regression 
Results 
Among 18,010 children (median age, 4.5 years; girls, 50%; half were girls), 1528 (8.5%) died, 3333 
(18.5%) transferred, 1633 (9.1%) were LTFU, and 11,516 (63.9%) remained in care. Half of the 
deaths were within 6-months of therapy (mortality rate=9.17, 95% CI: 8.55-9.84 per 100 PY). 10-
year survival probability %( 95%CI) was 88.9 (88.3-89.5) overall, 83.7 (82.5-84.8) in children aged 
<2 years, 91.9 (90.7-93.0) in those 2-4 years, 92.6 (91.5-93.6) in 5-9 years and 88.8 (9 87.2-90.2) in 
10-14 years. The 10-year survival probability in Botswana was 91.7(89.1-93.7), 89.8(88.1-91.2) in 
Eswatini, 86.9(85.2-88.4) in Lesotho, 86.5(84.9-88.0) in Malawi and 90.7(89.6-91.6) in Uganda. In 
Tanzania, the 5-year survival probability was 89.5(88.0-90.9). The risk factors of mortality were: 
baseline age <2 years (aHR 1.41(95% CI: 1.11-1.79) compared to 10-14 years; WHO stage 4 (aHR 
2.95(95% CI 2.33-2.72) and stage 3 (aHR 1.36(95% CI: 1.06-1.73) compared to stage 1 and 2 
disease;  severe (aHR=6.71, 95% CI 5.29-8.52) and moderate (aHR=2.64, 95% CI 1.90-3.66) 
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immune suppression compared to no/mild immune suppression; and  severe underweight (aHR 1.84 
(95% CI 1.48-2.29) compared to normal weight-for-age.  
 
Conclusion 
10-year survival in children receiving ART is good. Mortality is highest in the first 6-months of ART 
and young age (<2 years), advanced HIV disease and severe underweight at ART initiation were 
associated with a higher risk of early mortality. Our findings re-emphasize the need for early infant 
diagnosis and treatment and close monitoring during the first 6-months of therapy as measures to 
reduce mortality of HIV-infected children receiving ART. 
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INTRODUCTION 
For nearly one and a half decades, combination antiretroviral therapy (ART) has been the 
standard approach for treating pediatric HIV in the Eastern and Southern Africa region (ESA). Since 
its introduction in the region, ART has improved short-term survival of HIV-infected children 1-4.  
Additionally, several programmatic improvements that could further improve the survival of children 
have been implemented. For example, the 2015 WHO recommendation to initiate ART in all children 
upon diagnosis irrespective of disease severity have been implemented by countries, and more 
effective pediatric antiretrovirals (ARV’s) have become available over time5.  
 Despite the improved survival and programmatic improvements, in resource-limited settings, 
long-term pediatric ART care presents challenges that could affect the success of ART and long-term 
survival. For example, lack of appropriate pediatric ARV formulations, ARV stock outs, and health 
care workers need to adjust treatment doses as the child’s weight increases; yet, children may not 
adhere to clinic appointments 6, 7. Moreover, children are vulnerable because they depend on 
caregivers, who may be too sick to administer their medicines and as they grow into adolescents, they 
may not adhere to treatment 8, 9. All these challenges could lead to poor long-term adherence to ART, 
which can result in treatment failure, disease progression, and death.    
Even with over 10-years’ experience providing pediatric ART, data on long-term survival of 
children initiating ART are mainly from high and middle-income countries, and those from RLS are 
scarce; yet, challenges of providing pediatric ART in these settings may differ. Studies from high and 
middle-income countries report 5-10 year mortality rates of 1.2-1.7 deaths per 100 person-years and a 
survival probability of >94-99% 10-14. One study from Mozambique that examined survival in 
children receiving ART reported 8-years survival probability of 90% 15.  Limited data on long-term 
survival of children receiving ART in RLS precludes our understanding of the impact of ART 
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programs on long-term survival in HIV infected children, and yet significant investments have been 
made to improve survival in children with HIV.  
The Baylor International Pediatric AIDS Initiative (BIPAI) includes a network of seven 
clinical centers of excellence (COE) in six countries in Eastern and Southern Africa that have 
provided pediatric ART for over ten years 16. Data from the BIPAI network, therefore, provides an 
opportunity to examine long-term survival of children receiving ART.  Our study examined age-
specific survival at ten years of ART and risk factors for early mortality in HIV infected children who 
initiated ART between 2003-2017 in the BIPAI network clinics.  
METHODS 
Study design, setting, and population  
This study was a retrospective cohort study using patient-level data pooled from seven BIPAI 
COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. These COEs are operated in 
partnership with the respective governments and receive substantial funding for distribution of ART 
from the Presidential Emergency Plan for AIDS Relief (PEPFAR). They provide free comprehensive 
HIV/AIDS prevention and treatment services to children and adolescents with HIV. Children at all 
the COEs receive clinical care at least 3-monthly. Shorter clinic appointments are given at the start of 
therapy and when medically required.  The data at the sites are managed using a standardized 
electronic medical record system (EMR).  
We included children with HIV aged <15 years who initiated ART between January 2006 and 
June 2017 and had two or more follow-up visits after ART initiation. Children who were ARV 
experienced (except for exposure to ARVs for PMTCT) at entry into care were excluded. The cohort 
start date for Tanzania was 2010, corresponding to the period when the clinic became operational.  
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The individual patient data were pooled electronically, anonymized and transferred to the 
research team for cleaning and management. Ethical approvals (with a waiver of informed consent) 
were obtained from the individual country institutional review boards (IRB), Baylor College of 
Medicine IRB and University of Texas Health Science Center at Houston Committee for the protection 
of human subjects. 
Study variables and definitions  
  The independent study variables were age, sex, country, weight, height, WHO clinical stage, 
CD4 count, CD4 percent, weight for age Z-scores (WAZ), BMI for age Z scores (BAZ), ART 
regimens, TB diagnosis, hemoglobin levels(Hb) and immune suppression level. The child’s weight or 
height was considered to be at ART start if they were taken ± 1month from the ART start date, while 
WHO stage and CD4 count or percent at ART start were taken on or at a date closest to the ART 
initiation date within six months before and one month after ART initiation. We computed the WAZ 
for children aged < 10 years and BAZ for all children using the WHO child growth standards 17, 18. 
WAZ for children aged 10-14 years using the Centers for Diseases Control and Prevention (CDC) 
growth standards 19 because this measure was not available for the age group in the WHO growth 
standards. CD4 counts or CD4 percentage were categorized into immune suppression levels (no/mild, 
moderate or severe) for age according to the WHO classification 20, 21. The calendar period of ART 
initiation was categorized into three, 4-year periods: 2006-2009, 2010-2013 and 2014-2017 
corresponding to WHO guideline periods; 2014-2017 covered two guideline periods.  
The main outcome variable was all-cause mortality and was defined as death from any cause 
including HIV related and non-HIV related deaths. The date of death was extracted from the EMR. If 
the date was missing, we used the date the chart was closed. Other events that were censored in the 
analysis were lost to follow-up (LTFU), transfer out and active in care. The patient was considered 
LTFU if there was a gap of 90 days between their next clinic appointment and the database closure 
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date (December 31, 2017). The date of LTFU was the chart closure date, and if the chart was not 
closed, the patient was censored 90 days after the last scheduled appointment. The patient was 
considered transferred-out if the transfer was documented and the date of transfer was that recorded 
in the chart.  
Statistical analysis  
Patient characteristics at ART initiation were described using summary statistics (medians and 
proportions) by age groups (<2 years, 2-4 years, 5-9 years and 10-14 years). We computed overall 
mortality rates per 100 person-years(PY) and rates within the first six months of ART, at 6-24 months 
and after 24 months. Kaplan-Meier estimates for 10-year survival probability was calculated overall, 
by age group, country, and calendar period of ART initiation; differences in survival curves were 
tested using the log-rank test. Time to death was computed from the date of ART initiation, and 
children were right-censored at the earliest of either LTFU, transfer out, 10-years of follow-up or 
database closure date. We examined risk factors of mortality in the first 6-months and 6-24 months 
on ART using univariable and multivariable Cox proportional hazard regression models. We limited 
the analysis to the first 24 months to enable us to examine the effect of the most recent WHO- 
treatment guidelines (2014-2017) on survival. We used a stepwise regression method to select the 
most parsimonious model. The criteria for a variable to enter and to stay in the model were p≤0.15 
and p≤0.05, respectively. Known predictors of death, including WHO clinical stage, immune 
suppression level, and age were purposefully included in the analysis. We tested the proportional 
hazards assumption using the Schoenfield test. To avoid loss of information and biased estimates 
because of missing data, we imputed missing CD4, WHO stage, WAZ, and Hb values using multiple 
imputation by chained equations (MICE), using 20 cycles22, 23.  We conducted sensitivity analyses 
using complete case analysis and competing risks analyses with LTFU as the competing risk.    
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RESULTS  
Characteristics of participants  
 Overall, 23,510 children with HIV initiated ART between January 2006 and June 2017 at the 
BIPAI COEs, of whom 22,995 were <15 years of age. Of these, 4721 were excluded because they 
were not ART naïve at the time of enrollment in care at the study sites. These children transferred 
care to the study sites while they were already receiving ART and we did not have their baseline 
characteristics at ART initiation. In addition, we excluded 264 children who had only one medical 
visit after initiating ART, leaving 18,010 who were included in the study (Figure 1).  
 Table 1 describes patients’ characteristics at ART initiation by age group.  Of the 18,010 
children included in the study, half were girls and the median age was 4.5 [interquartile range (IQR): 
1.5-9.4] years. A third of all children were from Uganda and most initiated ART during 2010-2013. 
Most of the children (32.6%) were aged <2 years, 19.8% were 2-4 years, 25.7% 5-9 years and 21.9% 
were 10-14 years;   24.2% of all children had stage 4 disease, 17.8% had severe immune suppression, 
and 28.4% were severely underweight. Stage 4 disease, severe immune suppression and underweight 
were more frequent in the children <2 years than the other age groups (Table 1).  Among all children, 
86% initiated ART with nucleoside reverse transcriptase inhibitor (NNRTI) based regimens, but the 
frequency varied from 70% among infants to 95% among those aged 5-9 years. 
  The median duration of follow-up was 4.34 (IQR: 1.69-7.47) years with 85,140 person-years 
(PY) of follow-up overall. Of the overall person-time, 25,076 PY were of children aged <2 years, 
18,008 PY aged 2-4 years, 23,522 PY aged 5-9 years and 18,534 aged 10-14 years. During follow-up, 
1528 (8.5%) children died, 3333 (18.5%) transferred care to other health facilities, 1633 (9.1%) were 
LTFU, and 11,516 (63.9%) were still in care by the end of the study. Half of the deaths occurred 
within six months of ART and 78% within 2-years of ART. 
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Figure 1: Flow chart  
 
Mortality rates  
 The mortality rate among all children was 1.79 deaths per 100 PY. Mortality during the first 6 
months of receiving ART was 9.17 (95% CI: 8.55-9.84) deaths per 100 PY. The rate declined to 1.95 
(95% CI: 1.77-2.14) deaths per 100 PY between 6-month to 2 years and thereafter it reduced to 0.59 
(95% CI: 0.53-0.65) deaths per 100 PY. Mortality rates per 100 PY were 17.5 (95% CI: 16-19.2) in 
children <2 years, 6.8 (95% CI: 5.6-8.1) in 2-4 years, 4.7 (95% CI: 3.9-5.7) in 4-9 years and 4.8 (95% 
CI: 3.9-5.9) in the 10-14 year old. The combined probability of surviving up to 10-years on ART was 
88.9% (95% CI: 88.3%-89.5%). Children <2 years of age had the lowest 10-year survival probability 
[83.7% (95% CI: 82.5%-84.8%)] as compared to 91.9% (95% CI: 90.7%-93.0%) in those 2-4 years, 
92.6 % (95% CI: 91.5%-93.6%) in 5-9 years and 88.8% (95% CI: 87.2%-90.2%) (Figure 2).   
Initiated ART between 2006 and June 2017
N=23,510
ART-naive at enrollment 
n=22,995
ART-naive <15 yrs
n=18,274
ART naive <15 yrs
n=18,010
Only one medical visit, n=264
Not ART-naive at enrolment, n=4,721
Age at ART start ≥15years, n=515
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Table 1. Patient characteristics at ART start stratified by age. 
Characteristic 
Total                  
(N=18010) 
<2 years                
(N=5869) 
2-4 years                   
(N=3570) 
5-9 years                 
(N=4631) 
10-14 years           
(N=3940) 
Age, median(IQR) years 4.5(1.5-9.4) 1(0.6-1.5) 3.2(2.5-4.1) 7.6(6.3-8.8) 12.2(11.1-13.4) 
Sex, n (%)      
 Female 9046(50.2) 2916(49.7) 1711(47.9) 2313(50) 2106(53.5) 
 Male 8964(49.8) 2953(50.3) 1859(52.1) 2318(50.1) 1834(46.6) 
WHO clinical stage, n (%)      
 1&2 6783(37.7) 1810(30.8) 1288(36.1) 1792(38.7) 1893(48.1) 
 3 5607(31.1) 1650(28.1) 1186(33.2) 1673(36.1) 1098(27.9) 
 4 4363(24.2) 2036(34.7) 812(22.8) 812(17.5) 703(17.8) 
 missing  1257(7) 373(6.4) 284(8) 354(7.7) 246(6.2) 
Hemoglobin(mg/dl) 11.4(10-12.4) 10.6(9.2-11.8) 11.3(9.9-12.3) 11.7(10.7-12.7) 12.2(11.1-13.1) 
Immune Suppression, n (%)      
 None/mild 10490(58.3) 2791(47.6) 2171(60.8) 3182(68.7) 2346(59.5) 
 moderate 1891(10.5) 592(10.1) 286(8) 478(10.3) 535(13.6) 
 Severe 3206(17.8) 1567(26.7) 654(18.3) 429(9.3) 556(14.1) 
 missing  2423(13.5) 919(15.7) 459(12.9) 542(11.7) 503(12.8) 
Underweight, n (%)      
 None/mild/mod 12662(70.3) 3287(56) 2741(76.8) 3744(80.9) 2890(73.4) 
 Severe 5120(28.4) 2546(43.4) 775(21.7) 797(17.2) 1002(25.4) 
 missing  228(1.3) 36(0.6) 54(1.5) 90(1.9) 48(1.2) 
ART regimen, n (%)      
 NNRTI based 15481(86) 4123(70.3) 3168(88.7) 4430(95.7) 3760(95.4) 
 PI- based/other 2529(14) 1746(29.7) 402(11.3) 201(4.3) 180(4.6) 
Period of ART start, n (%)      
 2006-2009 6417(35.6) 2154(36.7) 1431(40.1) 1683(36.3) 1149(29.2) 
 2010-2013 7010(38.9) 2306(39.3) 1392(39) 1760(38) 1552(39.4) 
 2014-2017 4583(25.5) 1409(24) 747(20.9) 1188(25.7) 1239(31.4) 
Country, n (%)      
 Botswana 1062(5.9) 363(6.2) 94(2.6) 230(5) 375(9.5) 
 Eswatini 2153(12) 681(11.6) 411(11.5) 597(12.9) 464(11.8) 
 Lesotho 2831(15.7) 938(16) 465(13.1) 771(16.6) 657(16.7) 
 Malawi 3750(20.8) 1321(22.5) 843(23.6) 880(19) 706(17.9) 
 Tanzania 2557(14.2) 923(15.7) 460(12.9) 634(13.7) 540(13.7) 
 Uganda 5657(31.4) 1643(28) 1297(36.3) 1519(32.8) 1198(30.4) 
Outcomes, n (%)      
 Active in care 11516(63.9) 3230(55) 2253(63.1) 3248(70.1) 2785(70.7) 
 Died 1528(8.5) 799(13.6) 224(6.3) 230(5.0) 275(7.0) 
 Lost to follow-up 1633(9.1) 743(12.7) 362(10.1) 265(5.7) 263(6.7) 
 Transferred out 3333(18.5) 1097(18.7) 731(20.5) 888(19.2) 617(15.6) 
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Figure 2: Survival probability after initiating ART by age at initiation among 18,010 children 
with HIV in BIPAI COEs in six African countries, 2003-2017.  
 
Long-term survival by country and period of ART initiation 
Fig 3a and 3b show survival probabilities after initiating ART by country and by year of ART 
initiation respectively. Overall, there were significant country differences in 10-year survival 
(Log-rank p<0.01). The 10-year survival probabilities were similar in Botswana, Uganda, and 
Eswatini, and the survival probabilities in these countries were higher than those in Malawi and 
Lesotho. Children in Tanzania had not accrued up to 10 years of follow-up; however, at 5-years 
of follow-up, they had lower survival probability than those in Botswana and Uganda 
(supplementary table 1). The survival probabilities did not differ by year of ART initiation (Fig 
3b and Supplementary Table 1). 
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Figure 3: Survival probability after initiating ART by COE and period of initiation among 
18,010 children with HIV in BIPAI COE’s in six African countries, 2003-2017. By COE (a) and 
period of ART initiation (b) 
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Factors associated with mortality within six months of ART 
In multivariable regression analysis of short-term mortality, the factors associated with a 
higher risk of death were: being <2 years of age compared to age 10-14 years, stage 3 and stage 4 
disease compared to stage 1 or 2, moderate or severe immune suppression compared to no or 
mild immune suppression, underweight compared to normal weight for age (Table 2).  
Additionally, compared to Uganda, children who initiated ART in Lesotho had a higher risk of 
death, while those who initiated in Botswana, Malawi, and Tanzania had a lower risk of death. 
Children who initiated ART between 2014-2017 had a lower risk of death than those who 
initiated ART between 2006-2009, and an increase in hemoglobin levels was associated with a 
lower risk of death. There was no difference in risk between the ART regimens. Sensitivity 
analysis with complete case analysis and competing risks analysis found similar associations 
(supplementary table 2)  
Factors associated with mortality after between 6-24 month of receiving ART 
After six months on ART, age <2 years, time updated stage 3&4 disease stage, moderate 
or severe immune suppression and underweight continued to be associated with a higher risk of 
disease. Variables that were not significantly associated with death in the first six months of 
ART but became significant after six months are baseline age 5-9 years compared to age 10-14 
years, PI-based regimen compared to NNRTI-based regimen and initiating ART in 2010-2013 
compared to initiating in 2006-2009 (Table 2).  Except Malawi where the risk of death remained 
lower, there was no longer a difference in risk between other sites and Uganda. 
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Table 2: Risk factors for deaths within the first six months of ART and during 6-24months of ART.   
Characteristic  
0-6 months, N=18,010  6-24 months., N=16,289† 
No of 
deaths  
Mortality 
rate/ 100 
PY 
Univariableβ  Adjusted  
No of 
deaths  
Mortality 
rate/ 100 
PY 
Univariableβ   Adjusted 
HRδ           95%CI  HRδ       95% CI  HRδ           95%CI  HRδ       95% CI 
Age(years)                
 10-14 91 4.76 1   1   88 1.77 1   1  
 5-9 106 4.75 1.00 0.75, 1.32  1.13 0.85, 1.50  54 0.92 0.52 0.37, 0.73  0.71 0.50, 1.00 
 2-4 115 6.76 1.41 1.07, 1.86  1.00 0.76, 1.33  48 1.09 0.62 0.43, 0.88  0.78 0.54, 1.13 
 <2 471 17.5 3.62 2.9, 4.54  1.41 1.11, 1.79  233 3.63 2.04 1.6, 2.61  1.63 1.25, 2.13 
WHO clinical stage                 
 1&2 109 3.30 1   1   96 1.12 1   1  
 3 180 6.71 2.02 1.59, 2.56  1.36 1.06, 1.73  133 1.90 2.4 1.84, 3.13  1.64 1.25, 2.15 
 4 464 23.87 7.08 5.75, 8.72  2.95 2.33, 3.73  171 3.78 6.05 4.7, 7.78  2.52 1.91, 3.32 
Immune suppression level                
 None/mild 102 1.97 1   1    0.73 1   1  
 Moderate 63 7.01 3.52 2.57, 4.81  2.64 1.90, 3.66  104 2.07 5.16 3.51, 7.6  2.75 1.9, 3.99 
 Severe 426 30.83 15.09 12.16, 18.73  6.71 5.29, 8.52  46 6.97 10.24 7.43, 14.11  4.05 2.86, 5.72 
Hemoglobin mg/dl   0.65 0.63, 0.67  0.75 0.72, 0.78  201  0.69 0.66, 0.73  0.75 0.71, 0.79 
Underweight                
 None/mild 141 3.34 1   1   98 0.88 1   1  
 Moderate 142 7.45 2.22 1.75, 2.8  1.25 0.98, 1.59  78 1.59 2.05 1.53, 2.76  1.94 1.46, 2.59 
 Severe 491 21.31 6.25 5.18, 7.54  1.84 1.48, 2.29  244 4.52 6.85 5.32, 8.84  4.23 3.25, 5.52 
Regimen                
 NNRTI_based 618 8.40 1   1   362 1.90 1   1  
 PI_based 165 14.01 1.66 1.4, 1.97  0.86 0.71, 1.06  61 2.27 1.17 0.89, 1.54  0.67 0.49, 0.91 
Period of ART start                
 2006-2009 276 9.06 1   1   187 2.30 1   1  
 2010-2013 324 9.77 1.08 0.92, 1.26  1.17 0.98, 1.39  154 1.76 0.76 0.62, 0.94  0.75 0.59, 0.96 
 2014-2017 183 8.42 0.93 0.77, 1.12  0.77 0.62, 0.96  82 1.69 0.71 0.55, 0.92  0.67 0.49, 0.91 
Country‡                
 Uganda 239 8.83 1   1   100 1.39 1   1  
 Botswana 27 5.24 0.59 0.4, 0.88  0.62 0.41, 0.94  16 1.15 0.83 0.49, 1.4  0.62 0.36, 1.07 
 Eswatini 98 8.41 0.94 0.75, 1.19  1.05 0.82, 1.35  49 2.39 1.38 0.98, 1.95  0.94 0.65, 1.34 
 Lesotho 148 9.64 1.08 0.86, 1.37  1.28 1.03, 1.59  85 1.94 1.78 1.33, 2.37  1.21 0.89, 1.63 
 Malawi 170 11.04 1.25 1.01, 1.53  0.72 0.58, 0.90  104 2.49 1.72 1.31, 2.26  0.61 0.45, 0.82 
 Tanzania 101 9.69 1.09 0.89, 1.32  0.63 0.49, 0.80  69 2.41 1.7 1.25, 2.31  1.02 0.73, 1.43 
¥ 
PY- person-years; δHR- Hazard ratio; Bold figure show adjusted HR with p<0.05; β TB and sex were significant at univariable analysis and not at multivariable 
analysis. † Disease stage, immune suppression, underweight and hemoglobin measures were time-updated. ‡ Uganda was selected as a reference because it had 
the largest frequency.  
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Supplementary table 1: Kaplan-Meier estimates of survival probabilities % (95% CI) of 
children with HIV receiving antiretroviral therapy by age group, site and period of ART 
initiation.  
 
  Time to death from ART initiation 
Characteristic  6 months 2 years 5 years 10 years 
Age group       
 <2 years  91.8(91.1-92.5) 87.1(86.2-88.0) 85.2(84.2-86.1) 83.7(82.5-84.8) 
 2-4 years 96.7(96.1-97.3) 95.2(94.4-95.8) 93.5(92.5-94.3) 91.6(90.3-92.8) 
 4-9 years 97.7(97.2-98.1) 96.4(95.8-96.9) 95.1(94.4-95.7) 92.7(91.5-93.8) 
 10-14 years  97.7(97.1-98.1) 95.1(94.4-95.8) 92.9(92.0-93.7) 88.6(86.7-90.2) 
Country       
 Botswana 97.4(96.3-98.2) 95.8(94.4-96.9) 93.8(92.1-95.2) 91.7(89.1-93.7) 
 Eswatini 95.4(94.4-96.2) 92.7(91.5-93.8) 91.3(89.9-92.5) 89.8(88.1-91.2) 
 Lesotho 94.7(93.8-95.5) 91.3(90.2-92.3) 89.6(88.3-90.7) 86.9(85.2-88.4) 
 Malawi 95.3(94.6-96.0) 92.0(91.1-92.9) 89.8(88.7-90.8) 86.5(84.9-88.0) 
 Tanzania 96.0(95.1-96.7) 92.7(91.5-93.7) 89.5(88.0-90.9)  
 Uganda  95.7(95.2-96.2) 93.8(93.1-94.4) 92.6(91.9-93.3) 90.7(89.6-91.6) 
Period of ART initiation     
 2006-2009 95.6(95.1-96.1) 92.4(91.7-93.1) 90.5(89.7-91.2) 88.2(87.3-89.1) 
 2010-2013 95.3(94.8-95.8) 92.9(92.2-93.5) 91.3(90.5-91.9)  
 2014-2017 95.9(95.3-96.5) 93.7(92.9-94.4)   
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Supplementary table 2: Risk factors for death after complete care analysis and competing risk 
analysis. 
  Complete case analysis   Competing risk analysis‡ 
Characteristic  
0-6 months 
N=12332 
 6-24 month 
N=7246 
 0-6 months 
N=18010 
aHRδ       95% CI  aHRδ       95% CI  asHR¥       95% CI 
Age(years)         
 10-14 1   1   1  
 5-9 1.28 0.91, 1.79  0.80 0.43, 1.51  1.13 0.85, 1.50 
 2-4 0.79 0.55, 1.14  1.09 0.59, 2.00  1.00 0.76, 1.32 
 <2 1.42 1.06, 1.89  1.27 0.77, 2.09  1.4 1.1, 1.78 
WHO clinical stage          
 1&2 1   1 
  
1  
 3 1.44 1.07, 1.95  1.34 0.82, 2.18  1.36 1.06, 1.73 
 4 3.18 2.38, 4.24  2.78 1.75, 4.41  2.94 2.29, 3.77 
Severe immune suppression         
 None/mild 1   1 
  
1  
 Moderate 2.39 1.69, 3.39  3.23 1.91, 5.45  2.62 1.88, 3.65 
 Severe 6.82 5.34, 8.7  4.92 3.18, 7.60  6.62 5.16, 8.51 
Haemoglobin  mg/dl 0.73 0.7, 0.76  0.76 0.71, 0.83 
 
0.75 0.72, 0.78 
Underweight         
 None/mild 1   1 
  
1  
 Moderate 1.1 0.82, 1.47  1.15 0.70, 1.91  1.25 0.97, 1.61 
 Severe 1.58 1.22, 2.04  3.13 2.01, 4.86 
 
1.83 1.45, 2.32 
Regimen          
 NNRTI_based 1   1   1  
 PI_based 0.8 0.62, 1.04  0.69 0.34, 1.37 
 
0.87 0.7, 1.08 
Period of ART start         
 2006-2009 1      1  
 2010-2013 1.17 0.95, 1.45  0.55 0.34, 0.89 
 
1.17 0.99, 1.39 
 2014-2017 0.77 0.57, 1.05  0.40 0.19, 0.83 
 
0.78 0.63, 0.97 
Country          
 Uganda 1      1  
 Botswana 0.74 0.42, 1.32  0.34 0.08, 1.49 
 
0.64 0.42, 0.97 
 Eswatini 1.09 0.81, 1.46  0.62 0.31, 1.24 
 
1.07 0.83, 1.36 
 Lesotho 1.36 1.05, 1.76  0.82 0.44, 1.52  1.31 1.05, 1.62 
 Malawi 0.78 0.57, 1.05  0.82 0.44, 1.54  0.73 0.58, 0.92 
 Tanzania 0.42 0.3, 0.58  0.89 0.47, 1.66  0.62 0.49, 0.80 
δ aHR-adjusted hazard ratio; ¥sHR- sub distributional hazard ratio; ‡ Loss to follow-up was considered a 
competing risk. 
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DISCUSSION 
In this study, we report age-specific 10-year survival and factors associated with early 
mortality in a cohort of 18,010 children with HIV, who initiated ART between 2006 and 2017 in 
BIPAI clinics in six countries in Eastern and Southern Africa. We report three findings. First, the 
10-year survival probability of children living with HIV on ART was good (88.9%); however, 
children aged <2 years at baseline had poorer survival than older children, and this persisted 
beyond the first six months on ART. Second, mortality was highest in the first six months but 
declined after that.  Lastly, advanced disease stage, severe immune suppression and underweight 
were associated with increased risk of early mortality, but mortality risk was lower in children 
who initiated ART after 2010 compared to those initiated between 2006 and 2009. Our findings 
have important implications for programs implementing pediatric HIV care. The good long-term 
survival is encouraging and should motivate early testing and treatment initiation in children. 
Our findings also re-emphasize the need for early infant diagnosis; early treatment initiation and 
close monitoring during the first six months of therapy as critical measures to reduce mortality of 
children with HIV. 
 The overall 10-year survival probably in this study is similar to those reported in 
other studies in sub-Saharan Africa 15, 24; however, they are lower than those reported in high 
income countries 11, 12. The differences in survival are likely due to differences in quality of care 
notably better patient monitoring and treatment regimens. We found children < 2 years had the 
lowest 10-year survival probability (83%) and the risk of early death was higher in this age group 
compared to older children (figure 2 &supplementary table 1). Poor survival in children <2 years 
compared to older children has been reported previously 1, 3, 15, 24-33. The poor survival in these 
children may be attributed to rapid disease progression in infancy 34, 35, while higher survival in 
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older children may be attributed to survival bias. The children who initiated ART at older ages 
are those who had survived through infancy without receiving ART, and some may be “long-
term survivors” 36-38.  
Half of the deaths in our study occurred during the first 6 months on ART [mortality rate 
9.17 (95% CI: 8.55-9.84) deaths per 100 PY].  In addition to age <2 years, the other factors 
associated with a higher risk of death within the first six months were WHO stage 3 or 4, severe 
immune suppression and underweight, which are all markers of severe HIV disease. These 
findings imply these children initiated ART late. These findings, which have been reported in 
other studies 1, 3, 15, 25-30, highlight two important needs that should be addressed in order to 
mitigate early mortality in children with HIV. First, there is a need for continued efforts to 
diagnose and treat HIV in children early. Early diagnosis and treatment (within three months of 
birth) reduce mortality in infants by about 75% 39. Access to early testing is still a challenge in 
Eastern and Southern Africa. In 2017, only half of the HIV-exposed children in the study 
countries received a virological HIV test within 2-months of birth 40. Improving retention of 
mother-infant pairs in the postnatal period, integrating early infant diagnosis in child survival 
platforms like immunization programs and expanding access to the point of care testing could 
improve early testing. The current WHO treatment guidelines, which recommend initiating ART 
upon diagnosis irrespective of disease severity 5, provide an opportunity to initiate treatment 
early. Early treatment will only improve survival if the children are diagnosed early. 
In addition to early infant diagnosis, the second need is for close monitoring of children 
during the first 6-month period on ART and treating opportunistic infections. Although the WHO 
recently provided guidance for treating patients with advanced HIV disease 21, specific guidance 
for children under 5-year with advanced HIV disease was lacking. Updated data on frequent 
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causes of morbidity and deaths among children with advanced HIV in RLS are needed and 
intervention packages to reduce early mortality in these children may need to updated or 
developed.  
Encouragingly, we found that during the first two years on ART, mortality decreased 
with increasing calendar period of ART initiation. In the multivariable analysis, the risk of death 
in the first six months of ART was similar in children who initiated ART between 2010 and 2013 
compared to those initiated in 2006-2017, but lower in those who initiated ART between 2014 
and 2017. Among children who survived beyond 6 months, the risk of death was lower in those 
who initiated ART in 2010 and beyond compared to those who initiated ART between 2006-
2009 (table 2). This finding is unlikely due to better regimens and current guideline changes 
because regimens and disease severity characteristics were controlled for in the analysis. The 
finding may, therefore, represent a general improvement in care for children as health workers 
become better trained and more confident treating children with HIV, and use of better 
monitoring strategies, e.g., using viral load which has been associated with better survival. Since 
2014, the studies sites have used viral load measurements to monitor treatment progress in 
children. Additionally, the reduced risk of death after 2010 may also be due to the general 
temporal improvements in survival in all children observed in the study countries 41.  
The major strength of our study is that it is one of the few multi-country studies in sub-
Saharan African that provides age-specific 10-year survival estimates of children receiving ART. 
This allowed us to evaluate the impact of routine treatment programs on the survival of children 
with HIV. Also, we were able to examine calendar periods that cover the most recent treatment 
guidelines.     
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Our study also has several limitations. First, up to 9% of our patients were LTFU, and 
there is a possibility of informative censoring due to loss to follow-up which would lead to 
underestimation of mortality. However, our sensitivity analysis treating loss to follow-up as a 
competing risk found similar results showing that our findings are robust. Second, we do not 
report causes of death; this is unfortunate as it would be helpful to guide intervention to reduce 
mortality. In RLS, causes of death are not well documented. Third, we used CDC growth 
standards to determine WAZ scores in children 10-14 years; this may have resulted in an 
overestimation of underweight in these children since the CDC growth standards are mainly 
based on measurement of growth in children in high-income countries. Lastly, our study was 
conducted in COEs, which have higher standards of care than the general population; thus, our 
mortality estimates may underestimate the mortality rates in children on ART.    
Despite these limitations, our study findings are important for improving survival in 
children. The finding that long-term survival in children is good should motivate the caretakers 
of at-risk children to test them for HIV and to start ART immediately upon diagnosis. Prognostic 
information is important for developing interventions to reduce early mortality. In addition, the 
data on age-specific long term survival on ART could be used to model pediatric HIV 
epidemiological estimates and life expectancy in children receiving ART. Lastly, our findings 
will also provide a benchmark against which future intervention and guidelines will be measured. 
CONCLUSION 
Our study shows that overall 10-year survival in children receiving ART is good but 
varies by age group. Mortality rates are highest in children aged < 2years and during the first six 
months of ART. Disease severity characteristics were associated with a higher risk of early 
mortality, and children who initiated ART after 2010 had a lower risk of mortality than those 
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who initiated before. In order to improve survival in children with HIV receiving ART, problems 
of late diagnosis and late treatment initiation should be addressed and close patient monitoring in 
the first six months of care should be emphasized.   
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ABSTRACT 
Introduction 
Although rapid ART initiation (initiating ART within 7-days of diagnosis) is associated with better survival, 
retention and viral suppression in adults, data on these benefits in children are limited. We examined the 
association between rapid ART initiation (same-day or 2-7 days versus 8-90 days from entry into care) in 
children and 24-month all-cause mortality or loss to follow-up (LTFU). 
Methods  
We retrospectively analyzed data of HIV-infected children who initiated ART between 2014-2017 at seven 
Baylor International Pediatric AIDS Initiative clinics in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and 
Uganda. We defined LTFU as having a gap of 90 days between the next clinic appointment and the database 
closure date (December 31, 2017). Follow-up time accrued from the ART initiation date to the earliest of 
LTFU, death, transfer out, 24 months of follow-up or the database closure date. We assessed the association 
between rapid ART initiation, and mortality or LTFU using the Fine and Gray’s sub-distribution hazard 
regression for competing risks, adjusting for known risk factors of mortality and LTFU.  
Results  
Of the 3,299 participants, 1,516 (46%) initiated ART within 8-90 days of entry into care, 1004 (20%) 
initiated ART within 2-7 days and 872 (24%) initiated ART on the same-day. Forty percent of the children 
were aged <2 years, and half were girls. Overall, 254 (7.7%) died, 306 (9.3%) children were LTFU, 315 
(9.6%) transferred care to another clinic and 2424 (73.5%) remained in care. The risk of mortality was 
similar between children who initiated ART on the same-day [adjusted sub distributional hazard risk (aSHR) 
=1.10, 95% CI 0.79, 1.75] and those who initiated within 2-7 days (aSHR=1.05, 95% CI 0.77, 1.43) 
compared to those who initiated within 8-90 days. The risk of LTFU was higher in children who initiated 
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ART on the same day (aSHR=1.86, 95% CI 1.39, 2.49) and those who initiated within 2-7 days (aSHR=1.83, 
95% CI 1.38, 2.43) compared to those who initiated within 8-90 days.  
Conclusion 
Rapid ART initiation in children is associated with an increased risk of LTFU but not mortality. This data 
suggest that rapid ART initiation in children is feasible but loss to follow-up should be addressed.  
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INTRODUCTION  
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) set ambitious targets described 
as “95-95-95” targets to end AIDS by 2030 1. These targets are that 95% of people living with HIV know 
their HIV status, 95% of those diagnosed with HIV initiate and sustain ART and 95% of those on ART 
achieve and maintain viral suppression. To attain these targets, children diagnosed with HIV must be linked 
to HIV care, promptly initiated on ART and retained in care. However, 20% of children with HIV are lost to 
follow up between diagnosis and ART initiation 2. After initiating ART, mortality ranges from 4.3-29% 3-6 
and loss to follow-up (LTFU) ranges from 2-39% 6-10. These high losses to follow-up and mortality, if not 
addressed, can preclude attainment of the 95-95-95 goals for children by 2030. 
 As a strategy to reduce loss to follow-up and mortality in people living with HIV, the World Health 
Organization in 2017 recommended initiating ART in all people with HIV within 7-days (including same-
day initiation in people who are ready) upon diagnosis and clinical assessment.11. This accelerated ART 
initiation also called rapid ART initiation. This recommendation for rapid ART initiation followed a 
systematic review of evidence from trials in adults that showed rapid ART initiation was associated with an 
increased likelihood of starting ART, reduced mortality, and better viral suppression and retention in care as 
compared to delayed initiation.12 
Although the WHO recommended rapid ART initiation in children as well, data on the effect of rapid 
ART initiation on outcomes of children were limited. Two trials conducted among hospitalized children 
showed no difference in mortality in children who initiated ART rapidly versus those on delayed initiation 13, 
14. These studies do not include children who are not severely ill, and they do not examine if rapid ART 
initiation is associated with loss to follow-up, yet, observational studies in adults show an increased risk of 
being lost to follow-up after rapid ART initiation compared to delayed ART initiation 15, 16.  
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Given the paucity of data on this topic in children, we examined whether rapid ART initiation was 
associated with mortality and loss to follow-up in a cohort of children with HIV who initiated ART between 
2014 and 2017 at Baylor International Pediatric AIDS Initiative (BIPAI) centers of excellence (COE) in six 
African countries.  
METHODS  
Study design  
We conducted a retrospective cohort study using electronic medical records of children with HIV, 
who initiated ART at seven BIPAI COEs in Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda. 
The study was approved by ethics committees and institutional review boards in each country, Baylor 
College of Medicine, and University of Texas Health Science Centre at Houston.  
Study setting and treatment program. 
The BIPAI COEs, which were started in partnership with respective governments, provide free 
HIV/AIDS treatment and prevention services to children and adolescents. In 2014 and June 2016, all the 
COEs except Uganda implemented 2013 WHO guidelines which recommended initiating ART in all 
children aged <5 years irrespective of disease severity. Children aged 5-14 years were initiated if they have 
stage 3 or 4 disease or CD4 count <500 cells/mm3.  After June 2016, they updated the guidelines upon 2015 
WHO recommendations to initiate ART in all children <15 years irrespective of disease severity. Uganda 
implemented the guidelines to initiate ART in all children <15 years irrespective of disease severity from 
2014. 
At the COEs, caretakers of children receive pre-ART adherence counseling before initiating the 
children on ART. Older children and adolescents, who are disclosed to and know their HIV status, usually 
participate in the counseling session. Those who are ready to initiate ART receive medication on the same 
day, while those who are not ready are given an appointment within seven days for another session and are 
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then initiated if ready. If the client is not ready after 7-days, the next appointment is given within the next 
month on a mutually agreed date. Patients who do not return for appointments are tracked. After ART 
initiation, the children are reviewed at two weeks, at one month and after that 3-monthly if they are 
medically stable. Shorter appointments are given if medically indicated or if more psychosocial support and 
counseling are required.     
Study participants and data collection 
We included ART-naive HIV-infected children aged <15 years who entered HIV care at the study 
sites between January 2014 and 2017 and initiated ART within 90 days of enrollment. Ninety days was the 
median time to ART initiation observed among patients diagnosed at enrollment in a global study of access 
to ART in children 2. However, we also assumed that if children were eligible at enrollment, ART should be 
initiated at most within 90-days. We excluded children who initiated ART less than 6-months from the 
database closure date (December 31, 2017).  The individual patient data were pooled electronically, 
anonymized and transferred to the research team for cleaning and management.  
Variables and definitions  
Exposure: The exposure was the timing of ART initiation, which we categorized into same-day initiation, 2-
7 days and 8-90 days. ART initiation on the same-day and within 2-7 days are defined by WHO as rapid 
ART initiation 11. In our analysis, the reference group for comparison was those who initiated ART within 8-
90 days. 
Outcome: The outcomes of the study were all-cause mortality and loss to follow-up (LTFU). LTFU was 
defined as having a gap of 90 days between the next clinic appointment and the database closure date 
(December 31, 2017). The date of LTFU was the date the patient chart was closed in the EMR, and if the 
chart was not closed, the patient was censored 90 days after the last scheduled appointment. Censoring 
events were transferred out and active in care. The date of death and transfer out were the dates recorded in 
the EMR, and if missing, the date the chart was closed in the EMR was used. Children were considered 
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active in care if none of the other outcomes had occurred and they were assigned the date of the last visit as 
the outcome date. 
Other covariates: Other covariates considered were age, sex, country World Bank income category (middle 
income vs. low income), weight for age Z-scores (WAZ), TB diagnosis, WHO clinical disease stage (WHO 
stage) and immune suppression level and period of initiation (2014-2015 versus 2015-2016). The WAZ was 
computed from the weight taken on the ART start date. If weights were missing, weight taken ± 1month 
from ART start date was used. WAZ for children aged < 10 years were computed using the WHO child 
growth standards 17, 18 and for children 10-14 years using the Centers for Diseases Control and Prevention 
(CDC) growth standards 19. The CDC growth standards were used for children aged 10-14 years because this 
measure was not available in the WHO growth standards. CD4 counts or CD4 percentage cut were 
categorized into immune suppression level (no/mild, moderate or severe) for age according to the WHO 
classification 11, 20. The year of initiation was categorized as 2014-2015 and 2016-2017.  
Data analysis  
Baseline characteristics at ART initiation were summarized using frequencies and proportions for categorical 
variables, and medians and interquartile ranges (IQR) for continuous variables, stratified by the timing of 
ART initiation. We considered death and LTFU as competing risks events and estimated the 24-month 
cumulative incidence probabilities by the timing of ART initiation using competing risks survival analysis21-
23. Follow-up time accrued from the ART initiation date to the earliest of LTFU, death, transfer out, 24 
months of follow-up or the database closure date (December 31, 2017). We assessed the association between 
rapid ART initiation and 24-months’ mortality and LTFU using the Fine and Gray’s sub-distribution hazard 
regression model for competing risks adjusting for covariates21. Covariates were selected using stepwise 
regression setting the criteria for a variable to enter and stay in the model at p=0.15 and p=0.05, respectively. 
Known risk factors of mortality and LTFU were purposefully included in the mortality and LTFU analysis 
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respectively.  We imputed missing CD4, WHO clinical stage, WAZ, and hemoglobin values using multiple 
imputation by chained equations (MICE), using 20 cycles 24, 25. 
 
RESULTS  
Characteristics at study participants at ART initiation 
A total of 5,919 children enrolled in HIV care during the study period, of whom 5,483 initiated ART. 
Of these, we excluded 18 children who were ≥15 years at ART initiation, 1,426 who were not ART naïve at 
enrollment, 397 who initiated ART <6 months before the end of the observation period, 213 who initiated 
ART after 90 days and 107 had only one medical visit. Patients who initiated ART after 90 days had less 
advanced HIV/AIDS than those who initiated ART in less than 90-days (data not shown). The available 
sample size after all exclusions was 3,299 participants (Figure 1). Among the 107 children had only one 
visit, of whom 93 (86.9%) were initiated on the same-day, 8 (7.5%) within 2-7 days and six (5.6%) within 8-
90 days. Upon tracking, 47 (44%) had died, five (4.6%) had self-transferred out, and 55 (51.6%) were lost to 
follow-up (results not shown). Those who died, died within 5-days of initiating ART. 
Table 1 describes the characteristics of the study participants stratified by the timing of ART 
initiation. Of the 3,299 participants, the majority 1,516 (46%) initiated ART within 8-90 days of entry into 
care, 1004 (20%) initiated ART within 2-7 days and 872 (24%) initiated ART on the same-day they enrolled 
into care.  Forty percent of the children were aged <2 years, half were girls and the majority were from low-
income countries. WHO clinical stage was similar across the strata with nearly equal distribution of children 
with stage 1/2 and stage 4 disease. About 23.8% of patients had missing immune suppression (CD4) data. 
The proportion of missing data was highest in those who initiated ART on the same day (40.7%). This is no 
surprise since the guidelines in 2013 recommended immediate ART for all children <5 years and in 2015, all  
children <15 years irrespective of CD4 count, so pre-ART CD4 tests were no longer mandatory.  
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During 57,153 person-months, 254 (7.7%) died, 306 (9.3%) children were LTFU, 315 (9.6%) 
transferred care to another clinic and 2424 (73.5%) remained in care.  
Fig 1. Flow diagram of the inclusion criteria of the children with aged <15 years in the study and outcomes 
in each stratum of ART.  
Enrolled in HIV care between 2014 and 2017
N=5,901
Initiated ART
N=5,465
ART_naive and aged  <15 years at ART initiation
N=4,021
Total included in analysis
N=3299
8-90 days
N=1,516 (46%)
Outcomes at 24months,n(%)
Active in care 2424(73.5)
Died 254(7.7)
Lost to follow-up       306(9.3)
Transferred out 315(9.6)
1-7 days
N=1,004 (30%)
Outcomes at 24months,n(%)
Active in care            735(73.2)
Died 79(7.9)
Lost to follow-up      117(11.7)
Transferred out 73(7.3)
Same day initiation 
N=779(24%)
Outcomes at 24months,n(%)
Active in care 535(66.7)
Died 65(8.3)
Lost to follow-up   101(13.0)
Transferred out         78(10.0)
Started ART<6 month before closing database, n=397
Time from enrolment to ART initiation >90days, n=218
One medical visit, n=107
Age at ART start ≥15years, n=18
Not ART-naive at enrolment, n=1,426
Did not initiate ART, n=436
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Table 1: Baseline characteristics of participants at ART initiation. 
Characteristic same-day initiation               
N=779 
2-7 days                             
N=1004 
8-90 days              
N=1516 
Total                  
N=3299 
Age n (%)      
<2 year 369(47.4) 347(34.6) 597(39.4) 1313(39.8)  
2-4 years 138(17.7) 253(25.2) 285(18.8) 676(20.5)  
5-9 years 159(20.4) 246(24.5) 309(20.4) 714(21.6)  
10-14 years 113(14.5) 158(15.7) 325(21.4) 596(18.1) 
Sex, n (%)      
Female 415(53.3) 523(52.1) 754(49.7) 1692(51.3)  
Male 364(46.7) 481(47.9) 762(50.3) 1607(48.7) 
WHO clinical stage, n (%)     
 
1&2 285(36.6) 367(36.6) 597(39.4) 1249(37.9)  
3 142(18.2) 197(19.6) 363(23.9) 702(21.3)  
4 286(36.7) 436(43.4) 540(35.6) 1262(38.2)  
missing  66(8.5) 4(0.4) 16(1.1) 86(2.6) 
Haemoglobin(mg/dl)  
median(IQR) 
10.7(9.3-11.9) 10.9(9.5-12) 10.8(9.5-12) 10.8(9.4-12) 
Immune suppression, n (%)      
None/mild 246(31.6) 509(50.7) 714(47.1) 1469(44.5)  
Advanced 82(10.5) 93(9.3) 198(13.1) 373(11.3)  
Severe 134(17.2) 219(21.8) 320(21.1) 673(20.4)  
missing  317(40.7) 183(18.2) 284(18.7) 784(23.8) 
Underweight, n (%)      
None/mild 328(42.1) 450(44.8) 715(47.2) 1493(45.3)  
mod 156(20) 239(23.8) 319(21) 714(21.6)  
Severe 292(37.5) 314(31.3) 482(31.8) 1088(33)  
missing  3(0.4) 1(0.1) 0(0) 4(0.1) 
ART regimen, n (%)      
NNRTI based 443(56.9) 706(70.3) 1013(66.8) 2162(65.5)  
PI- based/other 336(43.1) 298(29.7) 503(33.2) 1137(34.5) 
Period of ART start 
    
 2014-2015 344(44.2) 666(66.3) 1019(67.2) 2029(61.5) 
 2016-2017 435(55.8) 338(33.7) 497(32.8) 1270(38.5) 
WB Income level 
    
 Middle income 122(5.7) 57(5.7) 535(35.3) 714(21.6) 
 Low income 657(94.3) 947(94.3) 981(64.7) 2585(78.4) 
§ ART- antiretroviral therapy ‡ WB- World Bank  
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Timing of ART initiation and the risk of mortality and loss to follow-up 
There was a difference in risk of mortality between rapid ART initiation and delayed initiation; 
however, the rapid ART initiation was associated with a higher risk of LTFU than delayed initiation. There 
was no difference in the 24-months cumulative incidence (CI) of mortality by timing of ART:  same day 
initiation CI=9.9%, 95%CI 7.7%, 12.5%); 2-7 days CI=8.3%, 95% CI 6.7%, 10.2%, and 8-90 days CI=7.9%, 
95% CI 6.5%, 9.4%; p<0.4. The 24-month risk of mortality was similar between those who initiated ART on 
the same day or within 2-7 days compared to those who initiated ART within 8-90 days of entering care after 
adjusting for other risk factors (table 2).  
The 24-months cumulative incidence of LTFU was higher in children initiated on the same-day of 
entering care (16.3%, 95% CI 13.4%-19.5%) and those initiated within 2-7 days (13.3%, 95% CI 11.1%-
15.7%) compared to those initiated within 8-90 days (6.8%, 95% CI 5.5%-8.3%), p<0.001 (Figure 1b). The 
adjusted hazard risk of LTFU was higher in children initiated on the same-day and in those initiated within 
2-7 days compared to those initiated within 8-90 days (table 2). Compared to children initiated on ART 
within 8-90 days, the risk of LTFU in those initiated on the same-day was 1.86 times higher (aSHR=1.86, 
95% CI 1.39, 2.49) and the risk in those initiated within 2-7 days was 1.83 times higher (aSHR=1.83, 95% 
CI 1.38, 2.43).  
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Figure 2: The cumulative incidence of mortality (figure 1a) and loss to follow-up (figure 1b), by the timing 
of ART initiation among HIV infected children initiated on ART between 2014-2017 at BIPAI COEs in 6 
African countries 
Figure 2a 
Figure 2b 
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Table 2: Unadjusted and Adjusted all-cause mortality and loss to follow-up sub-distributional hazard 
ratios for the first two years of antiretroviral therapy, by the timing of ART. 
Timing of ART 
Events 
(n/N) 
CIF (%) 95%CI  
Unadjusted 
 
Adjusted§ 
sHR           95%CI sHR       95% CI 
Mortality  
8-90 days 110/ 7.85 6.5, 9.35  1   1  
2-7 days 79/ 8.32 6.67, 10.2  1.09 0.81, 1.45  1.05 0.77, 1.43 
same-day 65/ 9.91 7.67, 12.49  1.21 0.89, 1.65  1.10 0.79, 1.54 
Loss to follow-up all children  
8-90 days 88/ 6.83 5.52, 8.31  1   1  
2-7 days 117/ 13.29 11.12, 15.66  2.05 1.56, 2.71  1.83 1.38, 2.43 
same-day 101/ 16.32 13.43, 19.47  2.60 1.95, 3.45  1.86 1.39, 2.49 
§ 
Adjusted for age, immune suppressions, hemoglobin level, period of ART initiation and country income level. WHO clinical 
stage was adjusted for in mortality analysis only; ‡ Sensitivity analysis was conducted among patients who had 2 or more visits 
(N=3299). CIF- cumulative incidence function  
 
 DISCUSSION 
In this study of 3,299 HIV-infected children aged <15 years who initiated ART between 2014 and 
2017 at BIPAI COEs in 6 African countries, we found that in the first 24-months of ART, rapid ART 
initiation was associated with higher loss to follow-up but was not associated with mortality. Given the need 
to initiate ART early in children, our findings suggest that rapid ART initiation could be implemented 
without impacting mortality of children, but loss to follow-up should be addressed  
We found that rapid ART initiation (same-day and within 2-7 days)  was associated with higher 
LTFU compared to initiation within 8-90 days even after excluding children who had only one visit after 
initiating ART. Similar findings have been reported in observational studies among pregnant women with 
HIV who initiated ART on the same day as diagnosis 15, 16. In contrast, our previous study in public health 
facilities in Uganda found no difference in retention among children initiated on the same day and those in 
whom ART was delayed 26. However, our previous study was underpowered to detect a difference in 
retention between the groups; thus, the finding was inconclusive. Although  reasons why children who 
initiated ART on the same-day drop out of care are not well understood, a plausible reason is that the 
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caregivers of children initiated on the same-day were not ready but chose to accept either because it was 
offered or because they felt pressured by providers to start, and they dropped-off after starting. Lack of 
readiness to start and feeling pressured by providers to start ART on the same day has been reported as a 
reason for dropping off from care among adults 16, 27, 28. Caretakers of children may require time to reflect on 
the HIV-diagnosis in the child, the implications of life-long treatment and the need to disclose to their 
partner if they have not. 
We did not find an association between rapid ART initiation and mortality. This finding confirms 
findings from previous clinical trials conducted among hospitalized children 14, 29. Although these trials and 
our study report no association between rapid ART initiation and mortality, we found much lower mortality 
(9.9%) among children who initiated ART on the same-day compared to the mortality among children who 
initiated ART within 48hrs in the Kenyan trial (23%). This difference is because the Kenyan study was 
conducted among Hospitalized children while ours was among a combination of both ill and relatively 
healthy children. Although, the purpose for immediate ART initiation is to maximize benefits of ART in 
children, not observing higher mortality in the children who initiated ART within a week is a reassurance 
that it does not harm. Additional, half of the children initiated ART within a week, meaning that it is 
acceptable and is feasible to implement without. Other benefits of same-day initiation observed in clinical 
trials in adults that should be investigated in children include reduced time to viral suppression and reduce 
pre-ART loss to follow-up. 30-32  
We excluded children who had one visit after initiating ART on the assumption that they never 
established care. On further analysis, we found these children had higher odds of having advanced disease 
and those who died, died within 5-days of initiating therapy. Although we could not confirm, it is possible 
that these children were ill and possibility hospitalized. It is also possible that they would have died even if 
ART were not initiated. The WHO guidelines recommend that in ill children, management of acute 
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conditions should be prioritized over ART initiation 11. More work, however, is required to understand which 
children do not return to care after rapid initiation and why they do not return into care. Theory-based should 
be used to understand the underlying determinant of loss to follow up and develop evidence-based 
interventions to reduce loss to follow-up. Such approaches include intervention-mapping approach 33 
Several limitations need to be considered when interpreting our findings. First, patients reported as 
lost to follow-up may have died and were misclassified as LTFU. Our findings may, therefore, underestimate 
mortality. However, we are not certain if this bias would be differential or non-differential.  Second, our 
analysis of LTFU did not control for structural and psychosocial determinants of loss to follow-up like the 
distance traveled to the clinic, and hence there is potential for residual confounding; however, we cannot 
determine the direction. Third, we excluded patients who initiated ART after 90 days of enrolling into care. 
These patients were relatively healthy at ART start, and by excluding them from the reference group, we 
may have overestimated mortality in the patients who delayed ART initiation, thus biasing our mortality 
estimates towards the null. However, this group represented only 6% of the population, previous global 
analysis of time to ART found a median initiation time to ART of 1 month 2 and as programs implement 
ART guidelines 34, time to ART will be shorter; thus, our cut off time of 90 days is reasonable. Lastly, we 
excluded patients who had only one visit. These patients had higher odds of advanced disease; most had been 
initiated on the same day and those who died, died within five days. We may have underestimated mortality 
among those who initiated ART on the same day; however, given that most of these patients died within five 
days, we assumed they had not established HIV care 
Notwithstanding the limitations, findings from our study, which is conducted in a programmatic 
setting, have important implications for the implementation of the universal ART and rapid ART initiation 
guidelines in children. These findings suggest that in programmatic settings, it is feasible to implement rapid 
ART initiation in children; however, loss to follow should be addressed. To attain better outcomes in 
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children during the implementation of rapid ART initiation, ART initiation protocols that incorporate rapid 
diagnostic assessment, readiness assessment, and retention strategies should be developed and tested in 
programmatic settings. Because in untreated children HIV progression is fast and mortality is high 35-37, care 
should be taken not to over-delay ART in children and miss the benefits of ART. If the rapid ART initiation 
guidelines are implemented without approaches to reduced mortality and loss to follow-up, attaining the 95-
95-95 goals for children in 2030 may be elusive. 
CONCLUSION 
Our study shows that in the first 24-months of ART, rapid ART initiation is associated with worse 
loss to follow-up but did not affect mortality in children aged <15 years. Our findings suggest that rapid 
ART initiation in children is feasible, but loss to follow-up needs to be addressed. More research is required 
to develop approaches and models for implementing rapid ART initiation in children while maintaining good 
outcomes for children.  
  
107 
 
REFERENCES 
1. Fast-Track, Ending the AIDS Epidemic by 2030. Accessed April 18, 2019 at: [Internet]; 
c2014. Available from: 
http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. 
2. Desmonde S, Tanser F, Vreeman R, Takassi E, Edmonds A, Lumbiganon P, Pinto J, Malateste 
K, McGowan C, Kariminia A. Access to antiretroviral therapy in HIV-infected children 
aged 0–19 years in the international epidemiology databases to evaluate AIDS (IeDEA) 
global cohort consortium, 2004–2015: A prospective cohort study. PLoS Medicine 
2018;15(5):e1002565. 
3. Abrams EJ, Woldesenbet S, Soares Silva J, Coovadia A, Black V, Technau KG, Kuhn L. 
Despite access to antiretrovirals for prevention and treatment, high rates of mortality persist 
among HIV-infected infants and young children. Pediatr Infect Dis J 2017 Jun;36(6):595-
601. 
4. Fatti G, Bock P, Eley B, Mothibi E, Grimwood A. Temporal trends in baseline characteristics 
and treatment outcomes of children starting antiretroviral treatment: An analysis in four 
provinces in south Africa, 2004-2009. J Acquir Immune Defic Syndr 2011 Nov 1;58(3):e60-
7. 
5. Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, Prozesky H, Technau 
K, Eley B, Vaz P, et al. Early mortality and loss to follow-up in HIV-infected children 
starting antiretroviral therapy in southern Africa. J Acquir Immune Defic Syndr 2010 
Aug;54(5):524-32. 
6. Leroy V, Malateste K, Rabie H, Lumbiganon P, Ayaya S, Dicko F, Davies MA, Kariminia A, 
Wools-Kaloustian K, Aka E, et al. Outcomes of antiretroviral therapy in children in Asia 
and Africa: A comparative analysis of the IeDEA pediatric multiregional collaboration. J 
Acquir Immune Defic Syndr 2013 Feb 1;62(2):208-19. 
7. Abuogi LL, Smith C, McFarland EJ. Retention of HIV-infected children in the first 12 months 
of antiretroviral therapy and predictors of attrition in resource limited settings: A systematic 
review. PloS One 2016;11(6):e0156506. 
8. Fox MP, Rosen S. Systematic review of retention of pediatric patients on HIV treatment in 
low and middle-income countries 2008-2013. Aids 2015 Feb 20;29(4):493-502. 
9. Ben‐Farhat J, Schramm B, Nicolay N, Wanjala S, Szumilin E, Balkan S, Pujades‐Rodríguez 
M. Mortality and clinical outcomes in children treated with antiretroviral therapy in four 
African vertical programmes during the first decade of pediatric HIV care, 2001–2010. 
Tropical Medicine & International Health 2017;22(3):340-50. 
10. Gamell A, Glass TR, Luwanda LB, Mapesi H, Samson L, Mtoi T, Nyamtema A, Muri L, 
Ntamatungiro A, Tanner M, et al. Implementation and operational research: An integrated 
108 
 
and comprehensive service delivery model to improve pediatric and maternal HIV care in 
rural Africa. J Acquir Immune Defic Syndr 2016 Dec 15;73(5):e67-75. 
11. World Health Organization. Guidelines for managing advanced HIV disease and rapid 
initiation of antiretroviral therapy, July 2017. 2017. 
12. Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, Mills EJ, Meintjes 
G, Vitoria M, Doherty M, et al. Benefits and risks of rapid initiation of antiretroviral 
therapy. Aids 2018 Jan 2;32(1):17-23. 
13. Njuguna IN, Cranmer LM, Otieno VO, Mugo C, Okinyi HM, Benki-Nugent S, Richardson 
B, Stern J, Maleche-Obimbo E, Wamalwa DC. Urgent versus post-stabilization 
antiretroviral treatment in hospitalized HIV-infected children in Kenya (PUSH): A 
randomized controlled trial. The Lancet HIV 2018;5(1):e12-22. 
14. Archary M, Sartorius B, La Russa P, Sibaya T, Healy M, Bobat RA. Hiv-infected children 
with severe acute malnutrition early versus delayed art initiation. 2017. 
15. Chan AK, Kanike E, Bedell R, Mayuni I, Manyera R, Mlotha W, Harries AD, van 
Oosterhout JJ, van Lettow M. Same day HIV diagnosis and antiretroviral therapy initiation 
affects retention in option B prevention of mother‐to‐child transmission services at antenatal 
care in Zomba district, Malawi. Journal of the International AIDS Society 
2016;19(1):20672. 
16. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, Chirwa Z, 
Ng'ambi W, Bakali A, Phiri S, et al. Retention in care under universal antiretroviral therapy 
for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. Aids 2014 
Feb 20;28(4):589-98. 
17. World Health Organization. Child growth standards [Internet]; c2011 [cited 2019 February, 
25th]. Available from: https://www.who.int/childgrowth/software/en/. 
18. World Health Organization. Child growth standards [Internet]; c2007 [cited 2019 February, 
25th]. Available from: https://www.who.int/growthref/tools/en/. 
19. Centres for Diseases Control and Prevention [Internet]; c2016 [cited 2019 February/27th]. 
Available from: https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm. 
20. World Health Organization. WHO case definitions of HIV for surveillance and revised 
clinical staging and immunological classification of HIV-related disease in adults and 
children. 2007. 
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. 
Journal of the American Statistical Association 1999;94(446):496-509. 
109 
 
22. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multi‐state 
models. Stat Med 2007;26(11):2389-430. 
23. Satagopan J, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach A. A note on 
competing risks in survival data analysis. Br J Cancer 2004;91(7):1229. 
24. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and 
guidance for practice. Stat Med 2011;30(4):377-99. 
25. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure 
covariates in survival analysis. Stat Med 1999;18(6):681-94. 
26. Same day ART initiation does not reduce 12-month retention among HIV-infected children 
in Uganda. Journal of the international aids societyJOHN WILEY & SONS LTD THE 
ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W …; 2018. 
27. Kim MH, Zhou A, Mazenga A, Ahmed S, Markham C, Zomba G, Simon K, Kazembe PN, 
Abrams EJ. Why did I stop? barriers and facilitators to uptake and adherence to ART in 
option B HIV care in Lilongwe, Malawi. PloS One 2016;11(2):e0149527. 
28. Mbonye M, Seeley J, Nalugya R, Kiwanuka T, Bagiire D, Mugyenyi M, Namale G, Mayanja 
Y, Kamali A. Test and treat: The early experiences in a clinic serving women at high risk of 
HIV infection in Kampala. AIDS Care 2016;28(sup3):33-8. 
29. Langwenya N, Phillips TK, Brittain K, Zerbe A, Abrams EJ, Myer L. Same‐day 
antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression 
or engagement in care: A cohort study. Journal of the International AIDS Society 
2018;21(6):e25133. 
30. Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, Charlebois 
E, Camlin C, Kahn J, Chang W. Effects of a multicomponent intervention to streamline 
initiation of antiretroviral therapy in Africa: A stepped-wedge cluster-randomized trial. The 
Lancet HIV 2016;3(11):e539-48. 
31. Koenig SP, Dorvil N, Dévieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, Lavoile K, 
Perodin C, Apollon A, Duverger L. Same-day HIV testing with the initiation of 
antiretroviral therapy versus standard care for persons living with HIV: A randomized 
unblinded trial. PLoS Medicine 2017;14(7):e1002357. 
32. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, Sanne I, Bokaba D, 
Sauls C, Rohr J. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: The 
RapIT randomized controlled trial. PLoS Medicine 2016;13(5):e1002015. 
33. Eldredge LKB, Markham CM, Kok G, Ruiter RA, Parcel GS. Planning health promotion 
programs: An intervention mapping approach. John Wiley & Sons; 2016. 
110 
 
34. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: Recommendations for a public health approach. 
World Health Organization; 2016. 
35. Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of 
infected and uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. 
The Lancet 2004;364(9441):1236-43. 
36. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, Nalugoda F, 
Sewankambo N, Kiduggavu M, Wawer M, Gray R. Mortality in HIV-infected and 
uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir 
Immune Defic Syndr 2006 Apr 1;41(4):504-8. 
37. Munyagwa M, Baisley K, Levin J, Brian M, Grosskurth H, Maher D. Mortality of HIV‐
infected and uninfected children in a longitudinal cohort in rural south‐west Uganda during 
eight years of follow‐up. Tropical Medicine & International Health 2012;17(7):836-43. 
  
 
 
111 
 
CONCLUSIONS 
In these three studies conducted among HIV infected children (0-14 years) who initiated 
ART between 2003-2017 at seven Baylor International Pediatric AIDS Initiative centers of 
excellence in 6 Eastern and Southern African countries, we have described age- and site-specific 
trends in advanced disease at ART initiation. We also described 10-years survival and risk 
factors of early mortality and examined the association between rapid ART initiation and 
outcomes of HIV infected. 
We found that the between 2003-2017, trends proportion of children with advanced HIV 
disease at ART initiation varied age group and country. The proportion declined in children aged 
5-14 years, remained the same in those aged <2 years and increased slightly in those age 2-4 
years. We also found that over time children initiating ART in southern Africa sites were older 
and less severely ill, while those in Eastern Africa sites were younger and more severely ill. In 
addition, at the end of the observation period (2016-2017), most children initiated ART within 
one week of entry into care, but a substantial proportion initiated ART with advanced disease. 
Our study also found that about 88.9% of children with HIV will be alive ten years after starting 
ART, but survival was lower in children < 2years (83%). We also established that 50% of the 
deaths were within six months of starting therapy and that young age (<2 years), advanced HIV 
disease and being underweight were associated with advanced HIV disease. Lastly, we found 
that rapid ART initiation in children was independently associated with a higher risk of loss to 
follow-up after 24-months of ART but was not associated with mortality. 
Our findings have important implications for pediatric HIV prevention, care and treatment 
programs. First, our findings re-emphasize the need for more efforts to diagnose and initiate 
children on ART early, and the need to closely monitor children during the first 6-months of 
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ART as measures to reduce mortality in children with HIV.  Our finding that long-term survival 
in children is good should motivate the caretakers of at-risk children to test them for HIV and to 
start ART immediately upon diagnosis. Additionally, the data on age-specific long-term survival 
on ART could be used to model pediatric HIV epidemiological estimates and life expectancy in 
children receiving ART. Prognostic information can guide the development of interventions to 
reduce early mortality. Lastly, our study shows that rapid ART initiation can be implemented in 
children, but the high loss to follow-up should be addressed. 
As mentioned in our papers, the strength of our studies was the use of large dataset from 
multiple countries and spanning 5-periods of implementation of different WHO guidelines. This 
enable used to compared trends and outcomes across countries and different guideline 
implementation periods. In addition, our study also examines age-specific trends in advanced 
disease and long-term survival, and this enabled us to show how pediatric HIV program 
implementation and guidelines have differentially affected outcomes of different age groups of 
children. Our studies also had weaknesses that should be considered when interpreting our 
findings.  First, the generalizability of our findings should be treated with caution because our 
study sites are well resourced, better staffed and likely to have a higher quality of care than 
public health facilities. However, in some countries like Botswana, our the study site provide 
care to nearly a third of all children in the country, and this enhances generalizability. Second, as 
with most observational data, we had missing data for important variables; however, to avoid 
loss to information, we imputed missing values.   Third, in some of our analysis, there was 
potential for informative censoring due to loss to follow-up, but we conducted sensitivity 
analysis in one analysis that showed our results were robust and used competing risks analysis in 
other to address informative censoring. Lastly, in our analysis of the association between rapid 
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ART initiation and loss to follow-up, we did not adjust to structural and psychosocial 
determinants of loss to follow-up, which could have led to residual confounding. 
Future studies are required to identify interventions to reduce early mortality and loss to 
follow-up in children with HIV especially in the current era of “treat all” guidelines and rapid 
ART initiation. Such interventions should be theory-based and should focus on identifying and 
addressing health systems changes and individual behaviors required to improve implementation 
of pediatric HIV programs and improving outcomes. While the specific focus should be on 
pediatric HIV, the interventions should have far-reaching benefits, for example, improving 
systems for delivery of child survival interventions as a whole.   
In conclusion, although we show that long-term survival is HIV-infected children treated 
with ART is relatively good, children are still being diagnosed late and starting treatment late, 
early mortality is high, and a significant proportion is lost to follow-up. While programs can use 
the good survival outcome to motivate caretaker to test and initiate ART early in children, more 
work is required to diagnose, initiate and keep children with HIV in care if we are to achieve the 
95-95-95 goals by 2030.   
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